Boscalid; Denial of Objections, 5439-5450 [E8-1523]
Download as PDF
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
for judicial review may be filed, and
shall not postpone the effectiveness of
such rule or action. This action may not
be challenged later in proceedings to
enforce its requirements. (See section
307(b)(2).)
Environmental protection, Air
pollution control, Incorporation by
reference, Intergovernmental relations,
Ozone, Reporting and recordkeeping
requirements, Volatile organic
compounds.
Dated: December 18, 2007.
Bharat Mathur,
Acting Regional Administrator, Region 5.
For the reasons stated in the preamble,
part 52, chapter I, of title 40 of the Code
of Federal Regulations is amended as
follows:
I
PART 52—[AMENDED]
1. The authority citation for part 52
continues to read as follows:
I
Authority: 42 U.S.C. 7401 et seq.
Subpart O—Illinois
2. Section 52.720 is amended by
adding paragraph (c)(180) to read as
follows:
I
yshivers on PROD1PC62 with RULES
BILLING CODE 6560–50–P
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
Environmental Protection
Agency (EPA).
ACTION: Final order.
AGENCY:
SUMMARY: In this order, EPA denies
objections filed by the Natural
Resources Defense Council (‘‘NRDC’’) to
a final rule under section 408 of the
Federal Food, Drug, and Cosmetic Act
(‘‘FFDCA’’), (21 U.S.C. 346a),
establishing tolerances for the pesticide
boscalid on various leafy greens. NRDC
argues that EPA has unlawfully
removed the additional safety factor for
the protection of infants and children
required by Food Quality Protection Act
of 1996.
FOR FURTHER INFORMATION CONTACT:
Tony Kish, Registration Division,
(7505P), Office of Pesticide Programs,
Environmental Protection Agency, 1200
Pennsylvania Ave., NW., Washington,
DC 20460–0001; telephone number:
703–308–9443; e-mail address:
kish.tony@epa.gov.
I. General Information
A. Does this Action Apply to Me?
*
*
*
*
(c) * * *
(180) On January 10, 2007, Illinois
submitted revisions to its rules for the
Emission Reduction Market System.
These revisions assure that sources in
the Chicago area with potential
emissions of VOC between 25 and 100
tons per year will remain subject to the
program, irrespective of changes in the
area’s ozone nonattainment
classification or designation and any
associated changes in whether such
sources are defined to be major sources.
EPA is again deferring action on section
205.150(e).
(i) Incorporation by reference.
(A) The following sections of 35
Illinois Administrative Code Part 205, as
effective June 13, 2005: sections
205.120, 205.130, 205.150 (except for
205.150(e)), 205.200, 205.205, 205.210,
205.220, 205.300, 205.310, 205.315,
205.316, 205.318, 205.320, 205.330,
205.335, 205.337, 205.400, 205.405,
205.410, 205.500, 205.510, 205.610,
205.700, 205.730, 205.750, and 205.760.
[FR Doc. E8–806 Filed 1–29–08; 8:45 am]
[EPA–HQ–OPP–2005–0145; FRL–8347–3]
SUPPLEMENTARY INFORMATION:
Identification of plan.
*
40 CFR Part 180
Boscalid; Denial of Objections
List of Subjects in 40 CFR Part 52
§ 52.720
ENVIRONMENTAL PROTECTION
AGENCY
You may be potentially affected by
this action if you are an agricultural
producer, food manufacturer, or
pesticide manufacturer. Potentially
affected entities may include, but are
not limited to:
• Crop production (NAICS code 111),
e.g., agricultural workers; greenhouse,
nursery, and floriculture workers;
farmers.
• Animal production (NAICS code
112), e.g., cattle ranchers and farmers,
dairy cattle farmers, livestock farmers.
• Food manufacturing (NAICS code
311), e.g., agricultural workers; farmers;
greenhouse, nursery, and floriculture
workers; ranchers; pesticide applicators.
• Pesticide manufacturing (NAICS
code 32532), e.g., agricultural workers;
commercial applicators; farmers;
greenhouse, nursery, and floriculture
workers; residential users.
This listing is not intended to be
exhaustive, but rather provides a guide
for readers regarding entities that are
potentially affected by this action. Other
types of entities not listed in this unit
could also be affected. The North
American Industrial Classification
System (NAICS) codes have been
provided to assist you and others in
PO 00000
Frm 00019
Fmt 4700
Sfmt 4700
5439
determining whether this action might
apply to certain entities. If you have any
questions regarding the applicability of
this action to a particular entity, consult
the person listed under FOR FURTHER
INFORMATION CONTACT.
B. How Can I Access Electronic Copies
of this Document?
In addition to accessing an electronic
copy of this Federal Register document
through the electronic docket at https://
www.regulations.gov, you may access
this Federal Register document
electronically through the EPA Internet
under the ‘‘Federal Register’’ listings at
https://www.epa.gov/fedrgstr. You may
also access a frequently updated
electronic version of 40 CFR part 180
through the Government Printing
Office’s pilot e-CFR site at https://
www.gpoaccess.gov/ecfr.
C. How Can I Access Electronic Copies
of Materials in the Docket?
EPA has established a docket for this
action under docket identification (ID)
number EPA–HQ–OPP–2005–0145. To
access the electronic docket, go to
https://www.regulations.gov, select
‘‘Advanced Search,’’ then ‘‘Docket
Search.’’ Insert the docket ID number
where indicated and select the
‘‘Submit’’ button. Follow the
instructions on the regulations.gov web
site to view the docket index or access
available documents.
II. Introduction
A. What Action Is the Agency Taking?
In this order, EPA denies objections
filed by the Natural Resources Defense
Council (‘‘NRDC’’) to a final rule under
section 408 of the Federal Food, Drug,
and Cosmetic Act (‘‘FFDCA’’), (21
U.S.C. 346a), establishing tolerances for
the pesticide boscalid on various leafy
greens. (Ref. 1). NRDC argues that EPA
must retain an additional ten-fold (10X)
safety factor for the protection of infants
and children due to data showing that
juvenile animals are more sensitive than
adults. Retention of this additional
safety factor, NRDC contends, shows
that the tolerances are unsafe.
Additionally, NRDC contends that
EPA’s tolerance decision was arbitrary
and capricious because (1) EPA failed to
explain adequately its reason for not
applying a 10X safety factor for infants
and children and (2) the safe dose for
boscalid established by EPA is ‘‘clearly
contrary to the data . . . .’’ (Id. at 3-4,
7–8).
B. What Is the Agency’s Authority for
Taking This Action?
The procedure for filing objections to
tolerance actions and EPA’s authority
E:\FR\FM\30JAR1.SGM
30JAR1
5440
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
for acting on such objections is
contained in section 408(g) of the
FFDCA and regulations at 40 CFR part
178. (21 U.S.C. 346a(g)).
yshivers on PROD1PC62 with RULES
III. Statutory and Regulatory
Background
A. Statutory Background
1. In general. EPA establishes
maximum residue limits, or
‘‘tolerances,’’ for pesticide residues in
food under section 408 of the FFDCA.
(21 U.S.C. 346a). Without such a
tolerance or an exemption from the
requirement of a tolerance, a food
containing a pesticide residue is
‘‘adulterated’’ under section 402 of the
FFDCA and may not be legally moved
in interstate commerce. (21 U.S.C. 331,
342). Monitoring and enforcement of
pesticide tolerances are carried out by
the U.S. Food and Drug Administration
and the U.S. Department of Agriculture.
Section 408 was substantially rewritten
by the Food Quality Protection Act of
1996 (‘‘FQPA’’), which added the
provisions discussed below establishing
a detailed safety standard for pesticides
and additional protections for infants
and children.
EPA also regulates pesticides under
the Federal Insecticide, Fungicide, and
Rodenticide Act (‘‘FIFRA’’), (7 U.S.C.
136 et seq). While the FFDCA authorizes
the establishment of legal limits for
pesticide residues in food, FIFRA
requires the approval of pesticides prior
to their sale and distribution, (7 U.S.C.
136a(a)), and establishes a registration
regime for regulating the use of
pesticides. FIFRA regulates pesticide
use in conjunction with its registration
scheme by requiring EPA review and
approval of pesticide labels and
specifying that use of a pesticide
inconsistent with its label is a violation
of Federal law. (7 U.S.C. 136j(a)(2)(G)).
In the FQPA, Congress integrated action
under the two statutes by requiring that
the safety standard under the FFDCA be
used as a criterion in FIFRA registration
actions as to pesticide uses which result
in dietary risk from residues in or on
food, (7 U.S.C. 136(bb)), and directing
that EPA coordinate, to the extent
practicable, revocations of tolerances
with pesticide cancellations under
FIFRA. (21 U.S.C. 346a(l)(1)).
2. Safety standard for pesticide
tolerances. A pesticide tolerance may
only be promulgated by EPA if the
tolerance is ‘‘safe.’’ (21 U.S.C.
346a(b)(2)(A)(i)). ‘‘Safe’’ is defined by
the statute to mean that ‘‘there is a
reasonable certainty that no harm will
result from aggregate exposure to the
pesticide chemical residue, including
all anticipated dietary exposures and all
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
other exposures for which there is
reliable information.’’ (21 U.S.C.
346a(b)(2)(A)(ii)). Section 408 directs
EPA, in making a safety determination,
to ‘‘consider, among other relevant
factors– . . . . available information
concerning the aggregate exposure
levels of consumers (and major
identifiable subgroups of consumers) to
the pesticide chemical residue and to
other related substances, including
dietary exposure under the tolerance
and all other tolerances in effect for the
pesticide chemical residue, and
exposure from other non-occupational
sources.’’ (21 U.S.C. 346a(b)(2)(D)(vi)).
Section 408(b)(2)(C) requires EPA to
give special consideration to risks posed
to infants and children. Specifically,
this provision states that EPA ‘‘shall
assess the risk of the pesticide chemical
based on available information
concerning the special susceptibility of
infants and children to the pesticide
chemical residues, including
neurological differences between infants
and children and adults, and effects of
in utero exposure to pesticide chemicals
. . . .’’ (21 U.S.C. 346a(b)(2)(C)(i)(II) and
(III)). This provision further directs that
‘‘[i]n the case of threshold effects, . . .
an additional tenfold margin of safety
for the pesticide chemical residue and
other sources of exposure shall be
applied for infants and children to take
into account potential pre- and postnatal toxicity and completeness of the
data with respect to exposure and
toxicity to infants and children.’’ (21
U.S.C. 346a(b)(2)(C)). EPA is permitted
to ‘‘use a different margin of safety for
the pesticide chemical residue only if,
on the basis of reliable data, such
margin will be safe for infants and
children.’’ (Id.). The additional safety
margin for infants and children is
referred to throughout this order as the
‘‘children’s safety factor.’’
3. Procedures for establishing,
amending, or revoking tolerances.
Tolerances are established, amended, or
revoked by rulemaking under the
unique procedural framework set forth
in the FFDCA. Generally, the
rulemaking is initiated by the party
seeking to establish, amend, or revoke a
tolerance by means of filing a petition
with EPA. (See 21 U.S.C. 346a(d)(1)).
EPA publishes in the Federal Register a
notice of the petition filing and requests
public comment. (21 U.S.C. 346a(d)(3)).
After reviewing the petition, and any
comments received on it, EPA may issue
a final rule establishing, amending, or
revoking the tolerance, issue a proposed
rule to do the same, or deny the
petition. (21 U.S.C. 346a(d)(4)). Once
EPA takes final action on the petition by
either establishing, amending, or
PO 00000
Frm 00020
Fmt 4700
Sfmt 4700
revoking the tolerance or denying the
petition, any affected party has 60 days
to file objections with EPA and seek an
evidentiary hearing on those objections.
(21 U.S.C. 346a(g)(2)). If objections are
filed by a party other than the
petitioner, EPA is required to serve a
copy of any objections on the petitioner.
(Id.). EPA’s final order on the objections
is subject to judicial review. (21 U.S.C.
346a(h)(1)).
4. Other EPA statutory authority over
pesticides. EPA also regulates pesticides
under the Federal Insecticide,
Fungicide, and Rodenticide Act
(‘‘FIFRA’’), (7 U.S.C. 136 et seq). While
the FFDCA authorizes the establishment
of legal limits for pesticide residues in
food, FIFRA requires the approval of
pesticides prior to their sale and
distribution, (7 U.S.C. 136a(a)), and
establishes a registration regime for
regulating the use of pesticides. FIFRA
regulates pesticide use in conjunction
with its registration scheme by requiring
EPA review and approval of pesticide
labels and specifying that use of a
pesticide inconsistent with its label is a
violation of Federal law. (7 U.S.C.
136j(a)(2)(G)).
B. Evaluating the Safety of Tolerances
Through the Use of Risk Assessment
Including the Use of Safety Factors
1. In general. The process EPA
follows in evaluating FFDCA petitions
to establish tolerances and in
determining the safety of the petitionedfor tolerances includes two steps. First,
EPA determines an appropriate residue
level value for the tolerance taking into
account data on levels that can be
expected in food. Second, EPA
evaluates the safety of the tolerance
relying on toxicity and exposure data
and guided by the statutory definition of
‘‘safe’’ and the statutory requirements
concerning risk assessment. Only on
completion of the second step can EPA
make a decision on whether a tolerance
may be established. Below, EPA
explains in detail, the reasons for this
approach.
2. Choosing a tolerance value. In the
first step of the tolerance evaluation
process (choosing a tolerance value),
EPA reviews data from experimental
crop field trials in which the pesticide
has been used in a manner, consistent
with the draft FIFRA label, that is likely
to produce the highest residue in the
crop in question (e.g., maximum
application rate, maximum number of
applications, minimum pre-harvest
interval between last pesticide
application and harvest). (Refs. 2 and 3).
These crop field trials are generally
conducted in several fields at several
geographical locations. (Ref. 3 at pages
E:\FR\FM\30JAR1.SGM
30JAR1
yshivers on PROD1PC62 with RULES
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
5, 7, and Tables 1 and 5). Several
samples are then gathered from each
field and analyzed. (Id. at 53).
Generally, the results from such field
trials show that the residue levels for a
given pesticide use will vary from as
low as non-detectable to measurable
values in the parts per million (ppm)
range with the majority of the values
falling at the lower part of the range.
EPA uses a statistical procedure to
analyze the field trial results and
identify the upper bound of expected
residue values. This upper bound value
is used as the tolerance value. (Ref. 4).
(As discussed below, the safety of the
tolerance value chosen is separately
evaluated.).
There are three main reasons for
closely linking tolerance values to the
maximum value that could be present
from maximum label usage of the
pesticide. First, EPA believes it is
important to coordinate its actions
under the two statutory frameworks
governing pesticides. (See 61 FR 2378,
2379, January 25, 1996). It would be
illogical for EPA to set a pesticide
tolerance under the FFDCA without
considering what action is being taken
under FIFRA with regard to registration
of that pesticide use. (Cf. 40 CFR
152.112(g) (requiring all necessary
tolerances to be in place before a FIFRA
registration may be granted)). In
coordinating its actions, one basic tenet
that EPA follows is that a grower who
applies a pesticide consistent with the
FIFRA label directions should not run
the risk that his or her crops will be
adulterated under the FFDCA because
the residues from that legal application
exceed the tolerance associated with
that use. To further this goal, crop field
trials require application of the
pesticide in the manner most likely to
produce maximum residues. Second,
choosing tolerance values based on
FIFRA label rates helps to ensure that
tolerance levels are established no
higher than necessary. If tolerance
values were selected solely in
consideration of health risks, in some
circumstances, tolerance values might
be set so as to allow much greater
application rates than necessary for
effective use of the pesticide. This could
encourage misuse of the pesticide.
Finally, closely linking tolerance values
to FIFRA labels helps EPA to police
compliance with label directions by
growers because detection of an
overtolerance residue is indicative of
use of a pesticide at levels, or in a
manner, not permitted on the label.
3. The safety determination—risk
assessment. Once a tolerance value is
chosen, EPA then evaluates the safety of
the pesticide tolerance using the process
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
of risk assessment. To assess risk of a
pesticide, EPA combines information on
pesticide toxicity with information
regarding the route, magnitude, and
duration of exposure to the pesticide.
In evaluating a pesticide’s potential
hazards (e.g., liver effects,
carcinogenicity), EPA examines both
short-term (e.g., ‘‘acute’’) and longerterm (e.g., ‘‘chronic’’) adverse effects
from pesticide exposure. (Ref. 2 at 8–
10). EPA also considers whether the
‘‘effect’’ has a threshold - a level below
which exposure has no appreciable
chance of causing the adverse effect. For
non-threshold effects, EPA assumes that
any exposure to the substance increases
the risk that the adverse effect may
occur. At present, EPA only considers
one adverse effect, the chronic effect of
cancer, to potentially be a non-threshold
effect. (Ref. 2 at 8–9). Not all
carcinogens, however, pose a risk at any
exposure level (i.e., ‘‘a non-threshold
effect or risk’’). Advances in the
understanding of carcinogenesis have
increasingly led EPA to conclude that
some pesticides that cause carcinogenic
effects only cause such effects above a
certain threshold of exposure.
Once the hazard for a durational
scenario is identified, EPA must
determine the toxicological level of
concern and then compare estimated
human exposure to this level of
concern. This comparison is done
through either calculating a safe dose in
humans (incorporating all appropriate
safety factors) and expressing exposure
as a percentage of this safe dose (the
reference dose (‘‘RfD’’) approach) or
dividing estimated human exposure into
an appropriately protective dose from
the relevant studies (the margin of
exposure (‘‘MOE’’) approach). How EPA
determines the level of concern and
assesses risk under these two
approaches is explained in more detail
below. EPA’s general approach to
estimating exposure is also briefly
discussed.
a. Levels of concern and risk
assessment—i. threshold effects. In
assessing the risk from a pesticide’s
threshold effects, EPA evaluates an
array of toxicological studies on the
pesticide. In each of these studies, EPA
attempts to identify the lowest observed
adverse effect level (‘‘LOAEL’’) and the
next lower dose at which there are no
observed adverse affect levels
(‘‘NOAEL’’). Generally, EPA will use the
lowest NOAEL from the available
studies, taking into account the route
and duration of exposure, as a starting
point in estimating the level of concern
for humans for a given exposure
scenario (e.g., acute oral exposure). This
selected NOAEL is usually referred to as
PO 00000
Frm 00021
Fmt 4700
Sfmt 4700
5441
the Point of Departure. In estimating
and describing the level of concern,
however, the Point of Departure is at
times manipulated differently
depending on whether the risk
assessment addresses dietary or nondietary exposures. (Refs. 2 at 3–8; 5 at
8, 52–53; and 6).
For dietary risks, EPA uses the Point
of Departure to calculate a safe dose or
RfD. The RfD is calculated by dividing
the Point of Departure by applicable
safety or uncertainty factors. Typically,
a combination of safety or uncertainty
factors providing a hundredfold (100X)
margin of safety is used: 10X to account
for uncertainties inherent in the
extrapolation from laboratory animal
data to humans and 10X for variations
in sensitivity among members of the
human population as well as other
unknowns. Further, to account for
deficiencies in the database or the
results seen in the database, EPA has
traditionally added additional safety
factors on a case-by-case basis. The
FQPA amendments to FFDCA section
408 require an additional safety factor of
10X to protect infants and children (to
address data completeness and pre- and
post-natal toxicity concerns), unless
reliable data support selection of a
different factor. To some extent, the
FQPA safety factor addresses concerns
related to the factors driving EPA’s
traditional use of additional safety
factors.
In implementing FFDCA section 408,
EPA’s Office of Pesticide Programs, also
calculates a variant of the RfD referred
to as a Population Adjusted Dose
(‘‘PAD’’). A PAD is the RfD divided by
any portion of the FQPA children’s
safety factor that does not correspond to
one of the traditional additional safety
factors used in general Agency risk
assessment. (Ref. 5 at 13–16). The
reason for calculating PADs is so that
other parts of the Agency, which are not
governed by FFDCA section 408, can,
when evaluating the same or similar
substances, easily identify which
aspects of a pesticide risk assessment
are a function of the particular statutory
commands in FFDCA section 408.
Today, RfDs and PADs are generally
calculated for both acute and chronic
dietary risks although traditionally a
RfD or PAD was only calculated for
chronic dietary risks. Throughout this
document general references to EPA’s
calculated safe dose are denoted as a
RfD/PAD.
To quantitatively describe risk using
the RfD/PAD approach, estimated
exposure is expressed as a percentage of
the RfD/PAD. Dietary exposures lower
than 100 percent of the RfD/PAD are
generally not of concern.
E:\FR\FM\30JAR1.SGM
30JAR1
yshivers on PROD1PC62 with RULES
5442
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
For non-dietary, and often for
combined dietary and non-dietary, risk
assessments of threshold effects, the
toxicological level of concern is not
expressed as a safe dose or RfD/PAD but
rather as the margin of exposure (MOE)
that is necessary to be sure that
exposure to a pesticide is safe. To
calculate the MOE for a pesticide for a
given exposure scenario, the expected
human exposure to the pesticide is
divided into the dose identified as the
Point of Departure. A safe MOE is
generally considered to be a margin at
least as high as the product of all
applicable safety factors for a pesticide.
For example, if a pesticide needs a 10X
factor to account for interspecies
differences, a 10X factor for intraspecies
differences, and a 10X FQPA children’s
safety factor, the safe or target MOE
would be a value of at least 1,000. In
contrast to the RfD/PAD approach, the
higher the pesticide’s MOE, the safer the
pesticide would be considered.
Accordingly, if the target MOE for a
pesticide is 1,000, MOE’s for that
pesticide exceeding 1,000 would
generally not be of concern. Like RfD/
PADs, specific MOEs are calculated for
exposures of different durations. For
non-dietary exposures, EPA typically
examines short-term, intermediate-term,
and long-term exposures. Additionally,
non-dietary exposure often involves
exposures by various routes including
dermal, inhalation, and oral.
The RfD/PAD and MOE approaches
are fundamentally equivalent. For a
given risk and given exposure of a
pesticide, if the pesticide were found to
be safe under a RfD/PAD analysis it
would also pass under the MOE
approach, and vice-versa.
ii. Non-threshold effects. For risk
assessments for non-threshold effects,
EPA does not use the RfD/PAD or MOE
approach if quantitation of the risk is
deemed appropriate. Rather, EPA
calculates the slope of the dose-response
curve for the non-threshold effects from
relevant studies using a model that
assumes that any amount of exposure
will lead to some degree of risk. The
slope of the dose-response curve can
then be used to estimate the probability
of occurrence of additional adverse
effects as a result of exposure to the
pesticide. For non-threshold cancer
risks, EPA generally is concerned if the
probability of increased cancer cases
exceed the range of 1 in 1 million.
b. Estimating human exposure.
Equally important to the risk assessment
process as identifying hazards and
determining the toxicological level of
concern is estimating human exposure.
Under FFDCA section 408, EPA is
concerned not only with exposure to
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
pesticide residues in food but also
exposure resulting from pesticide
contamination of drinking water
supplies and from use of pesticides in
the home or other non-occupational
settings. (See 21 U.S.C.
346a(b)(2)(D)(vi)). There are two critical
variables in estimating exposure in food:
i. the types and amount of food that
is consumed; and
ii. the residue levels in that food.
Consumption is estimated by EPA based
on scientific surveys of individuals’
food consumption in the United States
conducted by the U.S. Department of
Agriculture. (Ref. 2 at 12). Information
on residue levels comes from a range of
sources including crop field trials; data
on pesticide reduction due to
processing, cooking, and other practices;
information on the extent of usage of the
pesticide; and monitoring of the food
supply. (Id. at 17).
In assessing exposure from pesticide
residues in food, EPA, for efficiency’s
sake, follows a tiered approach in which
it, in the first instance, conducts its
initial, screening-level exposure
assessment using the worst case
assumptions that 100 percent of the
crop in question is treated with the
pesticide and 100 percent of the food
from that crop contains pesticide
residues at the tolerance level. (Id. at
11). When such an assessment shows no
risks of concern, EPA’s resources are
conserved because a more complex risk
assessment is unnecessary and regulated
parties are spared the cost of any
additional studies that may be needed.
If, however, a first tier assessment
suggests there could be a risk of
concern, EPA then attempts to refine its
exposure assumptions to yield a more
realistic picture of residue values
through use of data on the percent of the
crop actually treated with the pesticide
and data on the level of residues that
may be present on the treated crop.
These latter data are used to estimate
what has been traditionally referred to
by EPA as ‘‘anticipated residues.’’ Use
of percent crop treated data and
anticipated residue information is
appropriate because EPA’s worst case
assumptions of 100 percent treatment
and residues at tolerance value
significantly overstate residue values.
(72 FR 52112, July 18, 2007; 71 FR
43906, 43909–43910, August 2, 2006).
In estimating pesticide exposure
levels in drinking water, EPA most
frequently uses mathematical water
exposure models rather than pesticidespecific monitoring data. (69 FR 30042,
30058, May 26, 2004). EPA’s models are
based on extensive monitoring data and
detailed information on soil properties,
crop characteristics, and weather
PO 00000
Frm 00022
Fmt 4700
Sfmt 4700
patterns. These models calculate
estimated environmental concentrations
of pesticides using laboratory data that
describe how quickly the pesticide
breaks down to other chemicals and
how it moves in the environment (i.e.,
does it bind to the soil or is it highly
water soluble). Although computer
modeling provides an indirect estimate
of pesticide concentrations, these
concentrations can be estimated
continuously over long periods of time,
and for places that are of most interest
for any particular pesticide. Modeling is
a useful tool for characterizing
vulnerable sites, and can be used to
estimate peak concentrations from
infrequent, large storms. Whether EPA
assesses pesticide exposure in drinking
water through monitoring data or
modeling, EPA uses the higher of the
two values from surface and ground
water in assessing overall exposure to
the pesticide. In most cases, pesticide
residues in surface water are
significantly higher than in ground
water.
Generally, in assessing residential
exposure to pesticides, EPA relies on its
Residential Standard Operating
Procedures (‘‘SOPs’’). (Ref. 7). The SOPs
establish models for estimating
application and post-application
exposures in a residential setting where
pesticide-specific monitoring data is not
available. SOPs have been developed for
many common exposure scenarios
including pesticide treatment of lawns,
garden plants, trees, swimming pools,
pets, and indoor surfaces including
crack and crevice treatments. The SOPs
are based on existing monitoring and
survey data including information on
activity patterns, particularly for
children. Where available, EPA relies on
pesticide-specific data in estimating
residential exposures.
C. Children’s Safety Factor Policy
As part of implementation of the
major changes to FFDCA section 408
included in the FQPA, EPA has issued
a number of policy guidance documents
addressing critical science issues. On
January 31, 2002, EPA released its
science policy guidance on the
children’s safety factor. (Ref. 5) [This
policy is hereinafter referred to as the
‘‘Children’s Safety Factor Policy’’]. The
Children’s Safety Factor Policy
emphasizes throughout that EPA
interprets the children’s safety factor
provision as establishing a presumption
in favor of application of an additional
10X safety factor for the protection of
infants and children. (Id. at 4, 11, 47, A–
6). Further, the policy notes that the
children’s safety factor provision
permits a different safety factor to be
E:\FR\FM\30JAR1.SGM
30JAR1
yshivers on PROD1PC62 with RULES
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
substituted for this default 10X factor
only if reliable data are available to
show that the different factor will
protect the safety of infants and
children. (Id.). Given the wealth of data
available on pesticides, however, the
policy indicates a preference for making
an individualized determination of a
protective safety factor if possible. (Id. at
11). The policy states that use of the
default factor could under- or overprotect infants and children due to the
wide variety of issues addressed by the
children’s safety factor. (Id.). Further,
the policy notes that ‘‘[i]ndividual
assessments may result in the use of
additional factors greater or less than, or
equal to 10X, or no additional factor at
all.’’ (Id.).
In making pesticide-specific
assessments regarding the magnitude of
the children’s safety factor, the policy
stresses the importance of focusing on
the statutory language that ties the
children’s safety factor to concerns
regarding potential pre- and post-natal
toxicity and the completeness of the
toxicity and exposure databases. (Id. at
11–12). As to the completeness of the
toxicity database, the policy
recommends use of a weight-of-theevidence approach which considers not
only the presence or absence of data
generally required under EPA
regulations and guidelines but also the
availability of ‘‘any other data needed to
evaluate potential risks to children.’’ (Id.
at 20). The policy indicates that the
principal inquiry concerning missing
data should center on whether the
missing data would significantly affect
calculation of a safe exposure level. (Id.
at 22; accord 67 FR 60950, 60955,
September 27, 2002) (finding no
additional safety factor necessary for
triticonazole despite lack of
developmental neurotoxicity (‘‘DNT’’)
study because the ‘‘DNT [study] is
unlikely to affect the manner in which
triticonazole is regulated.’’)). When the
missing data are data above and beyond
general regulatory requirements, the
policy states that the weight of evidence
would generally only support the need
for an additional safety factor where the
data ‘‘is being required for ‘cause,’ that
is, if a significant concern is raised
based upon a review of existing
information, not simply because a data
requirement has been levied to expand
OPP’s general knowledge.’’ (Ref. 5 at
23).
As to potential pre- and post-natal
toxicity, the Children’s Safety Factor
Policy lists a variety of factors that
should be considered in evaluating the
degree of concern regarding any
identified pre- or post-natal toxicity. (Id.
at 27–31). As with the completeness of
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
the toxicity database, the policy
emphasizes that the analysis should
focus on whether any identified pre- or
post-natal toxicity raises uncertainty as
to whether the RfD/PAD is protective of
infants and children. (Id. at 31). Once
again, the presence of pre- or post-natal
toxicity, by itself, is not regarded as
determinative as to the children’s safety
factor. Rather, the policy stresses the
importance of evaluating all of the data
under a weight-of-evidence approach
focusing on the safety of infants and
children. (Id.).
In evaluating the completeness of the
exposure database, the policy explains
that a weight-of-the-evidence approach
should be used to determine the
confidence level EPA has as to whether
the exposure assessment ‘‘is either
highly accurate or based upon
sufficiently conservative input that it
does not underestimate those exposures
that are critical for assessing the risks to
infants and children.’’ (Id. at 32). EPA
describes why its methods for
calculating exposure through various
routes and aggregating exposure over
those routes generally produce
conservative exposure estimates – i.e.
health-protective estimates due to
overestimation of exposure. (Id. at 40–
43). Nonetheless, EPA emphasizes the
importance of verifying that the
tendency for its methods to overestimate
exposure in fact were adequately
protective in each individual
assessment. (Id. at 44).
IV. The Challenged Tolerances
Boscalid is a fungicide used both on
agricultural food crops as well as turf.
It has a wide variety of agricultural uses
including berries, nuts, soybeans, and
various vegetables. (40 CFR 180.589(a)).
Tolerances have also been established to
cover inadvertent residues on various
other crops as a result of rotation of
these crops onto fields previously
treated with boscalid. (40 CFR
180.589(d)). On December 20, 2006,
EPA promulgated new boscalid
tolerances for residues in or on leafy
greens crop subgroup 4A, except head
and leaf lettuce, and leafy petioles crop
subgroup 4B. (71 FR 76185, December
20, 2006).
In promulgating these tolerances, EPA
assessed the risk from boscalid based on
aggregate boscalid exposure. Animal
studies indicated that repeat dosing
with boscalid resulted in effects in the
liver and/or thyroid in various species.
Mechanistic studies indicated that the
thyroid effects were derivative of
enzymatic effects on the liver. (Ref. 8 at
4). The chronic RfD/PAD was based on
the results of three studies that showed
similar effects at similar levels. (Id. at
PO 00000
Frm 00023
Fmt 4700
Sfmt 4700
5443
23–24). The boscalid database showed
no effects that were attributable to a
single dose, and thus boscalid was
deemed not to pose an acute risk.
Testing involving in utero and/or postnatal exposure of animals showed no
developmental or reproductive effects;
however, this testing resulted in some
findings of qualitative or quantitative
sensitivity with regard to body weight
effects in the young. EPA concluded
there was low concern regarding these
sensitivity findings for various reasons
including that clear NOAELs were
identified for these effects and the
effects were transient in nature or
inconsistent. EPA assessed exposure to
boscalid in food relying on the worst
case assumption that boscalid residues
in all crops to which boscalid may be
legally applied had residues at the
tolerance level.
EPA concluded that chronic
exposures to boscalid did not raise
safety concerns because the most highly
exposed population subgroup, children
1–2 years old, had exposures below the
PAD or safe dose (exposure was at 38
percent of the PAD). (71 FR 76188).
Short-term exposures from golf course
turf was also judged to be safe having a
MOE of 1,400. (Id.). EPA concluded the
cancer risk posed by boscalid was
negligible given the weak evidence of
carcinogenicity in animal studies. (Id. at
76189). In conducting these
assessments, EPA determined that the
children’s safety factor could be
removed because the database was
complete, there was low concern for
increased sensitivity in the young, and
exposure had been estimated in a
conservative fashion. (Id. at 76188).
V. NRDC’s Objections
On February 20, 2007, NRDC filed
objections to the December 2006 rule
establishing tolerances for boscalid on
various leafy greens. (Ref. 1). On May
21, 2007, NRDC supplemented and
expanded its objections by filing
comments during the comment period
held by EPA on NRDC’s initial
objections. (Ref. 9).
NRDC’s objections have two main
thrusts: (1) that EPA erred in removing
the children’s safety factor given the
finding of that young animals had
increased sensitivity to boscalid; and (2)
that EPA’s decision is arbitrary and
capricious due to a failure to adequately
explain its reasons for removing the
children’s safety factor and because
EPA’s selection of NOAELs and the RfD/
PAD ‘‘are clearly contrary to the data.’’
(Ref. 1).
With regard to increased sensitivity in
young animals, NRDC relied in its
objections principally on the EPA
E:\FR\FM\30JAR1.SGM
30JAR1
5444
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
finding in the DNT study that rat pups
had decreased body weight and
decreased body weight gain at a dose of
147 milligrams/kilogram of body
weight/day (mg/kg/day) whereas no
effects were seen in the maternal
animals even at the highest dose tested
(1,442 mg/kg/day). Further, NRDC cites
the rat reproduction study as evidencing
increased sensitivity in rat pups. Given
this sensitivity, NRDC argues that it was
wrong for EPA to rely on a study on
adult animals to set the RfD/PAD
without retaining the children’s safety
factor. In addition to arguing that EPA
did not give proper weight to its
findings of increased sensitivity to the
young, NRDC claims that EPA analyzed
the data in several studies in a manner
that understates the sensitivity of the
young and has selected a RfD/PAD that
is under-protective of the young.
(NRDC’s arguments on these points are
presented in more detail in Unit VII.A.
below.). EPA’s allegedly improper
analysis is cited as grounds for retaining
the children’s safety factor. NRDC
claims that if EPA had retained the
children’s safety factor it could not have
concluded that the boscalid tolerances
are safe.
NRDC makes no new arguments to
justify its claim that EPA’s decision is
arbitrary and capricious; rather, NRDC
merely cross-references its earlier
assertions regarding EPA’s
interpretation of science data.
In its comments on its objections,
NRDC expands on these arguments.
First, it argues that EPA erred in
discounting the seriousness of the
increased sensitivity in the DNT and rat
reproduction studies. NRDC claims that
EPA’s analysis is based on nothing more
than speculation. (Ref. 9 at 2–4).
Second, NRDC cites a third study as
showing sensitivity in young animals,
the rabbit developmental study, and
argues similarly that EPA has relied on
nothing more than speculation to
conclude that the demonstrated
sensitivity is of low concern. Finally,
NRDC provides greater detail in support
of its argument that EPA’s selection of
a RfD/PAD for boscalid is not protective
of children and does not justify removal
of the children’s safety factor.
yshivers on PROD1PC62 with RULES
VI. Public Comments
Upon receipt of the objections, EPA
provided a copy of the objections to the
tolerance petitioner, BASF Corporation,
as required by the statute. Further, on
March 28, 2007, EPA published a notice
of the availability of the objections and
established a 60–day comment period.
(72 FR 14551, March 28, 2007). Other
than from BASF, EPA received
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
significant comments only from NRDC –
commenting on its own objections.
BASF’s comments stressed that a
complete database had been submitted
on boscalid including neurotoxicity
studies that went beyond the core
toxicology database requirements. In
addition, BASF asserted that these
studies showed ‘‘no toxicologically
meaningful effects [in young animals]
were observed at a dose below one that
produced toxicity to the parental
animals.’’ (Ref. 10 at 2). BASF
contended that effects in rat pups in the
DNT and the two-generation
reproduction study that occurred at
doses lower than effects in maternal
animals were small and/or transient
decreases in pup body weight. (Id.).
Because NRDC’s comments on its own
objections were a supplementation of its
objections, these comments were
provided to BASF and BASF was given
a 30–day period for response. (Ref. 11).
As to NRDC’s new arguments
concerning sensitivity in the young,
BASF asserts that the data did not
support that conclusion. As regards the
two-generation reproduction study and
the DNT, BASF notes that, although
toxicity in the parental animals was not
seen in the DNT study and was seen
only at the high dose in the
reproduction study, in the chronic/
carcinogenicity study in rat, where
systematic toxicity is examined more
thoroughly, adverse effects were seen at
doses corresponding to the mid and
high doses in the DNT and reproduction
studies. Thus, BASF concludes that the
findings of adverse effects in the young
at the mid and high doses in the DNT
and reproduction studies do not show
increased sensitivity in the young. As to
the rabbit developmental study, BASF
argues that, because the effects on the
fetuses (increased number of abortions)
occurred at a dose that showed the
maternal animals were under stress
(decreased weight gain), the study does
not show increased sensitivity in the
fetuses. According to BASF, ‘‘[t]he
rabbit is prone to spontaneously abort as
a response to maternal stress, and feed
restriction alone during the gestational
period may trigger abortions in rabbits.’’
(Id. at 3). Finally, BASF defends EPA’s
use of the NOAEL from the chronic dog
study as the Point of Departure for
setting the cRfD/PAD by presenting a
‘‘benchmark dose’’ analysis of the
relevant studies. Benchmark dose
analysis involves fitting a mathematical
model to the dose response data for the
purpose of estimating the threshold
effect level (i.e., the no adverse effect
level) reflecting a selected benchmark
response (e.g., 5%, 10%). BASF’s
benchmark dose analysis revealed that
PO 00000
Frm 00024
Fmt 4700
Sfmt 4700
the NOAEL from the chronic dog study
was lower than the benchmark dose
from DNT and two-generation
reproduction studies.
VII. EPA’s Response to the Objections
For the reasons stated below, EPA
denies each of NRDC’s objections.
A. NRDC’s Challenge to EPA’s
Children’s Safety Factor Determination
NRDC contends that EPA’s decision to
remove the children’s safety factor was
erroneous based on (1) the legal
argument that whenever EPA identifies
increased sensitivity in the young it is
required to retain the full 10X children’s
safety factor; and (2) the scientific claim
that EPA did not have a reasoned basis
for its conclusion that the sensitivity
identified in animal studies was of low
concern in evaluating whether the 10X
children’s safety factor should be
retained or a different factor selected.
Before reaching the merits of these
arguments, one preliminary matter
needs to be addressed. In a prior order
on an objection to EPA’s removal of the
children’s safety factor as to different
pesticides, EPA denied the objection
where retention of the children’s safety
factor would not have altered EPA’s
conclusion on the pesticide’s safety (72
FR 39318, 39323–39324, July 18, 2007).
For boscalid, the retention/removal
decision appears to be critical to the
safety determination because EPA
concluded that chronic exposure to
boscalid for the highest exposed
population subgroup is at 38 percent of
the RfD/PAD. If no other change is made
to the boscalid risk assessment other
than retaining the 10X children’s safety
factor, then the calculation that boscalid
exposure uses 38 percent of the RfD/
PAD for the most highly-exposed
subgroup would increase by a factor of
10. Because of the conservativeness of
the exposure assessment for boscalid
(assuming all foods that may be legally
treated bear tolerance level residues),
however, EPA strongly suspects that a
more realistic exposure assessment will
not show a risk of concern. Exposure
refinements from the worst case
assumptions of all foods containing
tolerance level residues generally
reduce exposure estimates by an order
of magnitude or more. (70 FR 46706,
46732, August 10, 2005). Nonetheless,
because EPA has not completed a
revised risk assessment for boscalid at
this time, it will address in this order
the substance of NRDC’s challenge to
EPA’s decision on the children’s safety
factor. It should be noted that EPA’s
decision on the children’s safety factor
for boscalid relied in part on the
conservativeness of EPA’s exposure
E:\FR\FM\30JAR1.SGM
30JAR1
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
assessment. This consideration
continues to be relevant, even if, at this
point, it does obviate NRDC’s objection
entirely.
1. NRDC’s legal argument. NRDC
argues that, because section 408
‘‘requires that the additional FQPA
tenfold safety factor ‘shall be applied’ to
‘take into account’ ‘potential pre- and
post-natal toxicity,’’ . . . [t]he clear
evidence that juveniles are significantly
more vulnerable than adults compels
EPA to retain or increase the default
FQPA tenfold safety factor for boscalid.’’
(Ref. 1 at 3).
On repeated occasions EPA has
rejected the interpretation that the
children’s safety factor provision
mandates that the absence of a
particular study or a finding of pre- or
post-natal toxicity or increased
sensitivity in the young removes EPA’s
discretion to choose a different safety
factor. (72 FR 52108, 52115–52117,
September 12, 2007; 71 FR 43906,
43919, August 2, 2006). EPA explained
its rationale recently in responding to
NRDC objections which made precisely
the same argument in this case:
yshivers on PROD1PC62 with RULES
The statute does direct EPA to consider
‘‘susceptibility of infants and children’’ to
pesticides. (21 U.S.C. 346a(b)(2)(C)(i)(II)). It
also states that an additional safety factor to
protect infants and children shall be applied
‘‘to take into account potential pre- and postnatal toxicity . . . .’’ (21 U.S.C. 346a(b)(2)(C)).
Nonetheless, in clear and unmistakable
language, Congress decreed that,
‘‘[n]otwithstanding such requirement for an
additional margin of safety’’ to take into
account potential pre- and post-natal toxicity,
EPA is authorized to choose a different safety
factor if EPA has reliable data showing a
different factor is safe. (Id.). Interpreting the
statute as creating a rigid, per se rule that the
identification of sensitivity in the young
removes EPA’s discretion to choose a
different safety factor is inconsistent with
this language and the flexibility granted to
the Agency.
(72 FR at 52117). NRDC has raised no
arguments in its current objections
which convince EPA to vary from its
long-held interpretation.
2. NRDC’s scientific argument. NRDC
makes five claims as to why the
evidence on increased sensitivity in the
young is of such significance that it was
inappropriate for EPA to remove the
children’s safety factor. NRDC also
argues that an alleged lack of reliable
data supporting EPA’s derivation of the
boscalid RfD/PAD demonstrates that it
was unlawful to remove the children’s
safety factor. Each claim is addressed in
turn below.
a. The degree of increased sensitivity
seen in the DNT. NRDC claims that
adverse effects on auditory startle reflex
were seen at all doses in the offspring
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
in the DNT study and thus the dose EPA
identified as a NOAEL for the offspring
(14 mg/kg/day) is actually a LOAEL.
According to NRDC, this demonstrates a
higher degree of sensitivity in the
offspring. NRDC notes that a draft EPA
assessment of the DNT study concluded
that there were adverse effects on the
auditory startle reflex in offspring at all
tested doses. The final EPA review of
the DNT study took the opposite
position: that there was not a significant
effect on the auditory startle reflex at
any dose. NRDC argues that EPA’s final
review is flawed because EPA misused
data on the historical level of the
auditory startle reflex in rat controls in
other studies (‘‘historical control data’’).
According to NRDC, EPA erred by
comparing historical control data to the
results in the treated animals in the
boscalid DNT study to determine if the
treated animals varied from control
animals generally. NRDC argues that the
only valid use of historical control data
is as a check on whether there is a
problem with the controls in a
particular study.
EPA disagrees with NRDC’s analysis
and reaffirms its conclusion that
boscalid did not elicit an adverse effect
on auditory startle reflex in the DNT
study. In its initial analysis of the DNT,
an EPA reviewer concluded that there
were treatment-related decreases in
auditory startle reflex at all doses on
post-natal-day (‘‘PND’’) 24. This finding
was based on a statistically significant
decrease in auditory startle reflex in
males at both the low and high doses in
the first block of five trials and for the
average effect over all trials. The average
decrease was greater in the low dose
group (24%) than the high dose group
(19%). The mid-dose group had a
slightly lower decrease of 15%. In
females, a statistically significant effect
was only seen in the second block of the
low and mid-dose groups but no such
effect was seen for the average across
blocks. Again, there was no doseresponse effect in that greater decreases
were seen at the low dose than at the
mid or high dose. No statistically
significant effects on auditory startle
reflex were seen on PND 60. Noting the
‘‘limitations’’ in the data, the EPA
reviewer nonetheless tentatively found a
treatment-related effect at all doses.
In response to this tentative
conclusion, the boscalid registrant
submitted historical control data on
auditory startle reflex and data
concerning one male pup that died on
PND 25. After examining the historical
control data, EPA concluded that the
auditory startle reflex of the controls
from the boscalid DNT study were
similar to historical controls and thus
PO 00000
Frm 00025
Fmt 4700
Sfmt 4700
5445
the controls from the boscalid study
‘‘should be considered the primary
source for analysis and consideration’’
for this study. (Ref. DER at 30). As to the
rat which died, EPA concluded that it
was suffering from an underlying illness
unrelated to treatment and removed its
data from the study. As a result, none
of the individual block trials nor the
average from all trials for males
evidenced a statistically significant
decrease in auditory startle reflex at
PND 24. EPA also reanalyzed the
statistical significance of the results for
the females and found a statistically
significant effect only at the low dose
for the second block. Given the revised
finding of a statistically significant
effect in only one block trial (out of five)
at one dose (out of three) in one sex on
one day of testing (out of two) and the
lack of a dose response (effects only at
the low dose), EPA concluded that there
was no treatment-related effect on
auditory startle reflex.
NRDC’s objection here is denied. As
a preliminary matter, EPA would note
that it disagrees with NRDC’s claim that
historical control data can only be used
for the narrow purpose of evaluating the
fitness of a study’s controls. (Refs. 12a,
12b, and 12c). This disagreement,
however, is beside the point because for
the boscalid DNT study EPA used
historical control data in precisely the
manner that NRDC argues they should
be used. EPA’s review of the DNT
specifically found that ‘‘[h]istorical
control data provided indicated that the
mean startle amplitude on PND 24 for
the current study of [boscalid] was
similar to the control means of the
submitted studies on PND 24. Therefore
the analysis of this group’s relation to
treatment groups is valid and should be
considered the primary source for
analysis and evaluation.’’ (Ref. 13 at 30).
Finally, EPA’s conclusion that the DNT
study showed no treatment-related
effect on auditory startle reflex was
based upon a reasonable evaluation of
the data, as demonstrated above.
b. The sensitivity of DNT Study.
NRDC claims that the DNT study is an
insensitive study because it involves
examination of only one male and one
female pup per litter and that therefore
EPA should have attached more
significance to the finding of increased
sensitivity in the young in that study.
NRDC also criticizes the statistical
analysis of the DNT study for only
including probability values (‘‘pvalues’’) representing confidence levels
of 95 percent (p-value of 0.05) and 99
percent (p-value of 0.01). (Basically, a pvalue defines the probability that an
observed difference between a control
group and a treatment group is based on
E:\FR\FM\30JAR1.SGM
30JAR1
yshivers on PROD1PC62 with RULES
5446
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
chance alone.). NRDC argues that rather
than analyze the data against the pvalues of 0.05 and 0.01, EPA should
calculate the ‘‘actual p-value statistic,’’
and thus EPA could use its ‘‘expert
judgment on the significance of the
findings, given the limitations of the
study.’’ (Ref. 1 at 5).
EPA believes that the significance
attached to findings of sensitivity in a
DNT study should be driven primarily
by an evaluation of the results of the
study itself. EPA would note that the
development and design of the DNT
study underwent an exhaustive
independent scientific peer review as
well as public comment process. (Ref.
14). This process included multiple
reviews by EPA’s FIFRA Scientific
Advisory Panel and public comment
opportunities as well as a scientific
workshop involving outside experts
organized expressly to evaluate
developmental neurotoxicity testing
issues. (Id.). NRDC’s criticisms of use of
reporting statistical significance at the
95 and 99 percent confidence levels are
misplaced. Use of p-values of 0.01 and
0.05 to document statistically significant
differences between treated and control
animal groups is a long-established
practice in the scientific community.
(Refs. 15a, 15b, 15c, 15d, and 15e). EPA
can calculate different levels of
statistical confidence if for some reason
the data suggest that may be valuable;
however, in EPA’s judgment no such
reasons were present in the
circumstances of the boscalid DNT
study.
c. Weight-of-the-evidence evaluation
of the two-generation reproduction
study in rats. NRDC argues that EPA
undervalues the importance of
increased sensitivity identified in the
two generation reproduction study in
rats based on nothing more than
speculation. According to NRDC, EPA
was just ‘‘guess[ing]’’ when it stated
that: ‘‘The degree of concern is also low
for the quantitative evidence of
susceptibility seen in the 2-generation
reproduction study in rats because the
decreases in body weight and body
weight gains were seen primarily in the
[second] generation. These may have
been due to exposure of the parental
animals to high doses (above the Limit
Dose).’’ (Ref. 9 at 2 (citing to 76 FR
76188) (emphasis added by NRDC)).
NRDC also suggests that EPA’s
‘‘speculation’’ is ‘‘nonsensical’’ because
if the second generation pups had
effects due to high dose exposures of the
parents, then these effects should have
been seen in the first generation pups
because their parents had the same high
dose exposures.
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
In comments on NRDC’s objections,
BASF argues that young animals are not
more sensitive to boscalid than adult
animals given that adult animals in the
chronic/carcinogenicity study in the rat
experienced adverse effects at similar
dose levels as the pups in the two
generation rat study. BASF makes the
same contention with regard to the DNT
study. (See Unit VII.A.2.d., below).
EPA does not believe that the
sensitivity evidenced in the pups in the
two-generation reproduction requires
retention of the 10X children’s safety
factor. As discussed in detail in Unit
VII.A.2.f., the NOAEL from the chronic
dog study used for the Point of
Departure in setting the chronic RfD/
PAD for the liver effects is protective of
the body weight effects seen in the
second generation male pups at mid and
high doses in the two-generation
reproduction study. EPA disagrees with
NRDC that it was somehow improper to
take into account that the body weight
effects in the pups in the two-generation
reproduction study were only seen in
males and only in the second
generation. These factors bear on
significance of the effects seen. Effects
seen in only one sex and only after
dosing for two generations are generally
regarded as less significant than effects
seen in both sexes and in both
generations of a two-generation study.
Moreover, there is other evidence from
the study suggesting that body weight
effects in the young were not entitled to
great weight in EPA’s weight-of-theevidence analysis. First, absolute body
weight and bodyweight gain of the male
F2 offspring of treated dams were
similar to those of the offspring of the
control dams at birth. Birth is a more
sensitive time point to indicate
susceptibility than subsequent time
periods. (Refs. 16a, 16b, and 16c).
Second, there was a lack of consistency
in the observed body weight decreases
(i.e, decreased on days 7 and 21 but not
on days 4 and 17). (Ref. 17 at 20). EPA
believes these factors are important to
informing its expert judgment regarding
the level of concern regarding, or the
significance of, the increased sensitivity
observed in this study. In any event,
EPA’s determination that the chronic
RfD/PAD is protective of the pup effects
seen in the reproduction study is alone
sufficient to allay any concerns
regarding increased sensitivity and preand post-natal toxicity raised by the
two-generation reproduction study.
NRDC places special emphasis on
EPA’s suggestion that the body weight
effect may be due to the very high dose
given the maternal animals. EPA’s
statement on this issue was in error
because, as noted, the body weight
PO 00000
Frm 00026
Fmt 4700
Sfmt 4700
effects were seen at both the mid and
high doses in the study in the second
generation pups. Nonetheless, for the
reasons described above, identification
of a clear NOAEL for body weight
effects and limited nature of the body
weight effects (e.g., one sex only,
inconsistent findings at the mid dose),
EPA concludes that the chronic RfD/
PAD based on a safety factor of 100X is
safe for infants and children.
EPA does not agree that BASF has
made an appropriate comparison of the
results of the two-generation
reproduction study and the chronic/
carcinogenicity study given the
substantial difference in time of
exposure to boscalid in the two studies.
d. Weight-of-the-evidence evaluation
of the DNT Study. NRDC argues that
EPA errs in downplaying the
significance of the decreased weight
gain in pups seen in the DNT. NRDC
states that EPA found there to be low
concern for the decreases in pup body
weight on post-natal days 1–4 because
no effects on body weight were seen at
any other time and the effects only
occurred when the maternal animals
were receiving an extremely high dose
(above the Limit Dose) suggesting that
pup effects were derivative of effects on
the maternal animals. This reasoning is
attacked by NRDC as mere speculation.
NRDC claims that ‘‘the Agency does not
and cannot assert that inadequate
weight gain on days 1–4 is an
insignificant adverse effect. Any
significant reduction in weight gain
during early development is potentially
harmful and may cause permanent
adverse effects.’’ (Ref. 9 at 3). Further,
NRDC states that EPA has presented no
empirical evidence to support its
conclusion that the high dose to the
maternal animals might have been the
reason for the pup effect.
For similar reasons to those relied
upon in rejecting NRDC’s arguments
concerning the two-generation
reproduction study, EPA does not
believe that the sensitivity evidenced in
the pups in the DNT study requires
retention of the 10X children’s safety
factor. As discussed in detail in Unit
VII.A.2.f., the NOAEL from the chronic
dog study used for the Point of
Departure in setting the chronic RfD/
PAD for the liver/thyroid effects is
protective of the transient body weight
effects seen in the pups at mid dose and
the more severe pup body weight effects
at the high dose in the DNT study. EPA
disagrees with NRDC that it was
somehow improper to take into account
that the body weight effects in the middose pups were transient in nature –
i.e., statistically significant decreases in
body weight were seen on post-natal
E:\FR\FM\30JAR1.SGM
30JAR1
yshivers on PROD1PC62 with RULES
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
days 1–4 but the animals had recovered
by day 11. The severity of an effect aids
in evaluation of the dose response curve
for a pesticide; in this case, it indicates
that mid dose was not far from the
actual no adverse effect level. In any
event, EPA’s determination that the
chronic RfD/cPAD is protective of the
pup effects seen in the DNT study is
alone sufficient to allay any concerns
regarding increased sensitivity and preand post-natal toxicity raised by the
DNT study.
NRDC challenges EPA’s reasoning
that the effects on pups’ body weight
may be due to the maternal animals
being exposed above the Limit Dose.
The Limit Dose is regarded as the
highest dose possible that can be given
an animal without overwhelming its
defense mechanisms. As a general
matter, EPA does not believe NRDC’s
argument is well-founded because
discounting the weight of effects seen
only at or above the Limit Dose is a
well-accepted scientific precept. Here,
however, EPA erred by mentioning the
Limit Dose because effects were present
in the pups at the mid dose as well as
at the dose that exceeded the Limit
Dose. Nonetheless, for the reasons
described above, identification of a clear
NOAEL for body weight effects and
limited nature of the body weight effects
(e.g., one sex only, transient nature of
effects at the mid dose), EPA concludes
that the RfD/PAD based on a safety
factor of 100X is safe for infants and
children.
For the same reason as stated in Unit
VII.A.2.c., EPA disagrees with BASF’s
comparison of the DNT study and the
chronic/carcinogenicity study.
e. Weight-of-the-evidence evaluation
of the rabbit developmental study.
NRDC claims that EPA wrongfully
disregards the qualitative evidence of
increased sensitivity seen in the rabbit
developmental study. According to
NRDC, EPA expressed a low degree of
concern for increased abortions or early
delivery effects on the young because
they were seen only at the Limit Dose
and may have been caused by maternal
stress. NRDC faults EPA for not
providing empirical evidence to support
this conclusion and argues that the
Limit Dose might not be the maximum
tolerated dose for boscalid in rabbits.
This type of ‘‘speculation,’’ NRDC
claims, cannot meet the ‘‘reliable data’’
requirement for choosing a different
children’s safety factor.
NRDC’s claims as to the rabbit
developmental study, have even less
merit than its arguments as to the twogeneration reproduction and DNT
studies. Not only is the chronic RfD/
PAD for the thyroid effects protective of
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
the qualitative sensitivity seen in the
rabbit developmental study but the
chronic RfD/cPAD is protective by an
order of magnitude of an effect seen
only at a ‘‘limit dose.’’ The chronic RfD/
PAD is based on a NOAEL from the
chronic dog study of 21.8 mg/kg/day as
compared to the NOAEL for the fetal
effects in the rabbit developmental
study of 300 mg/kg/day. The fetal effects
(abortions and early delivery) were seen
only at the Limit Dose. (Unlike in the
two-generation reproduction and DNT
studies, adverse effects were only seen
in the young at the high dose.).
Moreover, the fetal effects were seen
only in the presence of adverse effects
in the maternal animals. The primary
adverse effects in the maternal animals
were abortions and early delivery
(considered an adverse effect on both
maternal animals and fetuses) but the
study evidenced decreased food
consumption and decreased body
weight in the maternal animals as well.
Although a definitive conclusion was
not reached on whether the food
consumption effects were treatmentrelated, evaluation of the individual
animals showed that three of the four
does that aborted or delivered early
experienced dramatic reductions in food
consumption. Given these results, it was
reasonable for EPA to take into account
its scientific expertise with rabbit
toxicology studies which indicated that
maternal animals put under stress had
a tendency to abort or deliver early.
Based on all of this evidence, EPA
rejects NRDC’s arguments concerning
the rabbit developmental study and
concludes that the qualitative sensitivity
evidenced in the fetuses in the rabbit
developmental study does not require
retention of the 10X children’s safety
factor. (Refs. 18 and 19).
f. Derivation of the chronic RfD/PAD.
NRDC claims that EPA erred in its
selection of a NOAEL to calculate the
chronic RfD/PAD by not relying on the
lowest NOAEL from the applicable
chronic studies. (Ref. 1 at 5–6). NRDC
argues that, because EPA’s justification
for the RfD/PAD is allegedly nothing
more than speculation, EPA lacks the
reliable data necessary to remove the
children’s safety factor. (Ref. 9 at 4–5).
EPA relied on three co-critical studies
in selecting a NOAEL for the chronic
RfD/PAD: chronic toxicity in the rat,
carcinogenicity in the rat, and chronic
toxicity in the dog. Each of these studies
showed liver effects and the rat studies
also evidenced secondary effects on the
thyroid. The NOAELs for the studies
tightly bunched between 21.8 and 30
mg/kg/day. EPA selected the 21.8 mg/
kg/day NOAEL from the chronic dog
study to calculate the chronic RfD/PAD.
PO 00000
Frm 00027
Fmt 4700
Sfmt 4700
5447
EPA considered but rejected lower
NOAELs from three other studies: the
90–day subchronic toxicity study in the
dog; the two-generation reproduction
study in the rat; and the developmental
neurotoxicity study. EPA’s rationale for
not using the NOAELs from these
studies was that the lower NOAELs
from these studies were an artifact of
dose selection given the wide range
between NOAEL and LOAEL in the
studies and the minimal effects seen at
the LOAEL.
NRDC challenges EPA’s conclusion
claiming that EPA has ignored ‘‘effects
at significantly lower doses in juvenile
animals (2-gen repro and DNT).’’ (Ref. 1
at 4). NRDC also argues that EPA’s
decision is speculative because (1) ‘‘EPA
does not identify any reliable data to
support its theory that a 10x differential
between NOAELs and LOAELs – as
occurred [with the three studies with
lower NOAELs] – can never result from
well designed and conducted studies;’’
and (2) ‘‘EPA offers no reliable data to
support its assumption that the
relationship between the LOAELs and
NOAELs across studies with different
designs and with different test species
must always be the same . . . .’’ (Ref. 9
at 4).
NRDC’s arguments are without merit.
First, NRDC is wrong to contend that
EPA, in setting the chronic RfD/PAD,
ignored ‘‘effects at significantly lower
doses in juvenile animals’’ in the twogeneration reproduction study and the
DNT. EPA based the chronic RfD/PAD
on the chronic dog study. In that study
the lowest dose in which adverse effects
were seen was 57.4 mg/kg/day. On the
other hand, in the two-generation
reproduction study and the DNT, the
lowest doses at which adverse effects
were seen were 101.2 mg/kg/day and
147 mg/kg/day, respectively. (Ref. 18 at
17). Second, EPA is not contending, nor
does its analysis depend on, the
supposition that a ‘‘10x differential
between NOAELs and LOAELs . . . can
never result from well designed and
conducted studies.’’ The differential
between a study’s NOAEL and LOAEL
depends on the dose spacing in the
study – studies with more and closelyspaced doses are likely to yield a lower
differential than studies with fewer and
widely-spaced doses. EPA is not arguing
that it is inappropriate to design a study
with a factor of 10 between doses.
Third, EPA is not contending that the
relationship between NOAELs and
LOAELs across studies must always be
the same. Rather, EPA concluded that
the data for boscalid indicated that the
NOAEL it selected as the Point of
Departure for calculating the chronic
E:\FR\FM\30JAR1.SGM
30JAR1
5448
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
RfD/PAD would be protective of all
effects.
In making this conclusion, EPA relied
on several factors. First, EPA compared
the NOAELs and LOAELs of the six
chronic studies that had NOAELs that
were relatively close. This exercise is
appropriate because the NOAEL from
any one study is, in part, an artifact of
the dose selection process, and does not
identify the no adverse effect level just
the level at which no effects were
observed in the particular study. In
animal testing, animals are generally
dosed at three or four different levels.
The dose levels are fairly widely spread
(generally 2X – 10X) so that there is a
good chance of identifying both a
NOAEL and a LOAEL. The actual no
adverse effect level or lowest adverse
effect level will be somewhere between
the identified NOAEL and LOAEL.
When multiple studies produce results
in a similar range, they often can
provide valuable information about
where the true no adverse effect and
lowest adverse effect levels are. The
NOAELs and LOAELs for the six studies
are presented in Table 1.
TABLE 1.—SELECTED CHRONIC AND SUBCHRONIC STUDIES FOR BOSCALID
Study
NOAEL male/female (m/f) in mg/kg/day
LOAEL m/f in mg/kg/day
Chronic toxicity in rats
21.9/30
110/150.3
Carcinogenicity in rats
23/29.7
116.1/155.6
21.8/22.1
57.4/58.3
7.6
78.1
10.1/12.3 (offspring)
101.2/123.9 (offspring)
14 (offspring)
147 (offspring)
Chronic toxicity in dogs
Subchronic toxicity in dogs
Two-generation reproduction study in rats
yshivers on PROD1PC62 with RULES
DNT in rats
Just based on the dose spread alone,
the chronic dog study appears to
provide valuable information because it
has the tightest spread between NOAEL
and LOAEL.
Second, EPA considered the effects
seen in the studies. The NOAEL/
LOAELs for the chronic rat,
carcinogenicity rat, and chronic dog
studies were all based primarily on
effects on the liver and/or thyroid. The
other three studies had NOAEL/LOAELs
based on decreased body weight and
decreased body weight gain. The first
three studies also demonstrated body
weight effects but at the same or higher
doses than the organ effects. Organ
effects are generally judged to be of
more serious concern than systemic
toxicity as shown through body weight
effects. Given the heightened concern
with the liver and thyroid effects and
the fact that body weight effects only
occurred at the same or higher doses,
evaluation of the effects seen in the
studies also supported reliance on the
NOAEL from the chronic dog study.
Finally, EPA undertook a one-to-one
comparison of the chronic dog study
with the three studies that had a lower
NOAEL. Given that the subchronic dog
study was conducted in the same
species as the chronic dog study and
that the results of the subchronic dog
study were fully consistent with the
chronic dog study (i.e., based on the
chronic dog study it would be expected
that 7.6 mg/kg/day would be a NOAEL
and 78.1 a LOAEL), the subchronic dog
study supported reliance on the NOAEL
from the chronic dog study. Further, the
strength of the findings at the LOAEL in
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
the two-generation reproduction study
and the DNT study, did not suggest that
the actual no adverse effect level for the
effects seen in these studies is far below
the identified LOAEL. In the twogeneration reproduction and DNT
studies, the body weight effects at the
LOAEL were either transient in nature
(DNT study), not seen in both sexes
(two-generation reproduction study), or
not consistently seen post-natally (DNT
and two-generation reproduction
studies). (See Units VII.A.2.c.,
VII.A.2.d., and VII.A.2.e.).
Given the weight-of-the-evidence,
EPA concludes it was reasonable to
choose the NOAEL from the chronic dog
study in calculating the chronic RfD/
PAD. Contrary to NRDC’s contention,
this decision is not based on speculation
but on careful consideration of the
entire database – a complete database
that provides reliable data on which to
choose a safety factor that is protective
of the safety of infants and children. In
any event, EPA would note that
selecting the NOAEL from the DNT
study or the two-generation
reproduction study would not change
the safety conclusion on the boscalid
tolerances even without any further
refinement of the worst case exposure
assumptions relied upon in the
tolerance document. EPA estimated
exposure was at 38 percent of the
chronic RfD/PAD and a lowering of the
chronic RfD/PAD by a factor of two due
to reliance on the two-generation
reproduction study (i.e. using a NOAEL
of 10.1 mg/kg/day instead of 21.8 mg/
kg/day) would still show worst case
PO 00000
Frm 00028
Fmt 4700
Sfmt 4700
exposure to be below the chronic RfD/
PAD.
BASF, in its comments, presents a
benchmark dose analysis of the DNT
and two-generation reproduction
studies in support of EPA’s selection of
21.9 mg/kg/day as the Point of
Departure. The benchmark dose
calculated by BASF is supportive of
EPA’s decision in that all of the
benchmark doses covering various
endpoints in these two studies were
higher than 21.8 mg/kg/day. Although
BASF’s description of the method it
used for calculating these benchmark
doses appears scientifically appropriate,
BASF has not submitted supporting
documentation for its calculation and
EPA has not independently verified it.
3. Conclusion on children’s safety
factor. EPA disagrees both with NRDC’s
legal claim that a finding of sensitivity
always requires retention of the
children’s safety factor and factual
assertion that the particular evidence of
increased sensitivity on boscalid
requires such a result. NRDC’s legal
argument ignores the plain language of
the statute. NRDC’s factual argument
fails to take into account the entire
database.
EPA has a complete toxicity database
for boscalid. The toxicity studies for
boscalid show it generally to have low
mammalian toxicity and the database
reveals no reproductive or
developmental concerns, including no
developmental neurotoxic concerns.
Data involving the testing of young
animals did show increased quantitative
sensitivity in the young with regard to
body weight effects and qualitative
E:\FR\FM\30JAR1.SGM
30JAR1
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
yshivers on PROD1PC62 with RULES
sensitivity in one developmental study.
Clear NOAELs were identified for all of
these effects. Moreover, the body weight
effects at the LOAELs in these studies
were either transient or inconsistent and
qualitative sensitivity occurred at the
Limit Dose in the presence of maternal
toxicity. EPA reasonably concluded that
using the NOAEL from the chronic dog
study was protective of all of the effects
seen in the developmental and
reproduction studies. That the chronic
dog study only involved the testing of
adult dogs does not raise concerns for
the young because, as noted, EPA found
the NOAEL from that study to be
protective of the effects seen in all
studies with the young, and the effects
of concern in the dog study, increased
liver weights and hepatic enzyme
induction, are not common
developmental concerns. In any event,
when rats were exposed to boscalid preand post-natally as well as into
adulthood in the two generation
reproduction study, increased liver
weights were only seen at the Limit
Dose. Thus, increased sensitivity to liver
effects in the young is not a concern.
Finally, EPA has conservatively
estimated human exposure to boscalid,
relying on worst case exposures in food
(assuming all registered crops contain
residues at the tolerance level), and
conservative models as well as
pesticide-specific data in estimating
exposure from residues in drinking
water and from residential uses. Based
on consideration of all of these data,
EPA reasonably concluded it had
reliable data showing that infants and
children would be safe without
application of an additional 10X safety
factor.
B. NRDC’s Claim That EPA’s Decision is
Arbitrary and Capricious
NRDC argues that EPA’s tolerance
decision on boscalid was arbitrary and
capricious because (1) EPA failed to
adequately explain its safety factor
decision; and (2) ‘‘[t]he NOAELs and
cPAD established by EPA for boscalid
are clearly contrary to the data . . . .’’
(Ref. 1 at 7–8). In the section of its
objections addressing this claim, NRDC
provides nothing in support of its
assertion that EPA provided insufficient
explanation for its children’s safety
factor determination. Presumably,
NRDC is referring to the aspects of the
children’s safety factor determination
challenged in an earlier portion of its
objections and addressed by EPA in
Unit VII.A. of this order. Thus, EPA
relies on Unit VII.A. as responsive to
NRDC’s arbitrary and capricious claim
as to the children’s safety factor
decision, and denies the objection for
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
the reasons there stated. Similarly, to
the extent NRDC is arguing that EPA’s
selection of a NOAEL in the DNT study
or its selection of the NOAEL from the
chronic dog study as the Point of
Departure for deriving the chronic RfD/
PAD were arbitrary and capricious, EPA
denies this objection for the reasons
contained in Units VII.A.2.a. and
VII.A.2.f.
VIII. Regulatory Assessment
Requirements
As indicated previously, this action
announces the Agency’s final order
regarding objections filed under section
408 of FFDCA. As such, this action is an
adjudication and not a rule. The
regulatory assessment requirements
imposed on rulemaking do not,
therefore, apply to this action.
IX. Submission to Congress and the
Comptroller General
The Congressional Review Act, (5
U.S.C. 801 et seq.), as added by the
Small Business Regulatory Enforcement
Fairness Act of 1996, does not apply
because this action is not a rule for
purposes of 5 U.S.C. 804(3).
X. References
1. NRDC, ‘‘Objection To The
Establishment Of Tolerances For
Pesticide Chemical Residues Of
Boscalid Docket Id No. EPA–HQ–OPP–
2005–0145’’ (February 20, 2007).
2. Office of Pesticide Programs, U.S.
EPA, ‘‘Available Information on
Assessing Pesticide Exposure From
Food: A User’s Guide’’ (June 21, 2000).
3. U.S. EPA, ‘‘Residue Chemistry Test
Guidelines: OPPTS 860.1500 Crop Field
Trials’’ (August 1996).
4. Office of Pesticide Programs, U.S.
EPA and Pest Regulatory Management
Agency, Health Canada, ‘‘NAFTA
Guidance Document for Guidance for
Setting Pesticide Tolerances Based on
Field Trial Data ’’ (September 28, 2005).
5. Office of Pesticide Programs, U.S.
EPA, ‘‘Determination of the Appropriate
FQPA Safety Factor(s) in Tolerance
Assessment’’ (January 31, 2002).
6. Office of Pesticide Programs, U.S.
EPA, ‘‘The Use of Data on
Cholinesterase Inhibition for Risk
Assessments of Organophosphorous and
Carbamate Pesticides’’ (August 18,
2000).
7. Office of Pesticide Programs, U.S.
EPA, Versar Corporation, ‘‘Standard
Operating Procedures (SOPs) for
Residential Exposure Assessments’’
(Draft, December 19, 1997).
8. Office of Prevention, Pesticides and
Toxic Substances, U. S. EPA,
Memorandum from Yan Donovan to
Dennis McNeilly/R.Keigwin, ‘‘PP#
PO 00000
Frm 00029
Fmt 4700
Sfmt 4700
5449
1F06313 —Human Health Risk
Assessment for New Fungicide BAS 510
F (Common Name: Boscalid) —
Proposal for Tolerances for Residues in/
on Numerous Crops and Livestock
Commodities’’ (September 8, 2003).
9. NRDC, ‘‘Objection to the
Establishment of Tolerances for
Pesticide Chemical Residues of
Boscalid’’ (May 21, 2007.
10. BASF, ‘‘Docket ID Number EPA–
HQ–OPP–2005–0145: BASF Response to
NRDC Objection to Boscalid Pesticide
Tolerances’’ (May 29, 2007).
11. Email Communication, Bryant
Crowe, U.S. EPA to Khalid Akkari,
BASF, ‘‘Notification: Boscalid –
Objections’’ (July 10, 2007).
12a. W. Kaufmann. 2003. ‘‘Current
Status of Developmental Neurotoxicity:
An Industry Perspective.’’ Toxicology
Letters, 140–141; pages 161–169.
12b. U. Deschl, B. Kittle et al. 2002.
‘‘The value of historical control datascientific advantages for pathologists,
industry and agencies.’’ Toxicologic
Patholology, Vol. 30, number 1, pages
80–87.
12c. J.K. Haseman. 1995. ‘‘Data
Analysis: Statistical Analysis and Use of
Historical Control Data.’’ Regulatory
Toxicology and Pharmacology, Vol. 21,
pages 52–59.
13. Health Effects Division, Office of
Pesticide Programs, US EPA, ‘‘Data
Evaluation Record: Developmental
Neurotoxicity Study – Rat; BAS 910 F’’
(Date) (EPA Reviewer: William F. Sette).
14. U.S. EPA, ‘‘Response to Petition to
Compel the U.S. EPA to Repeal Its Test
Guidelines for Developmental
Neurotoxicity’’ (January 3, 2005)
(available at ‘‘https://docket.epa.gov/
edkpub/do /EDKStaffCollection
DetailView?objectId
=0b0007d480525f44)’’.
15a. H.L. Adler and E. B. Roessler
1977. ‘‘Introduction to Probability and
Statistics.’’ 6th ed. H. Freeman. New
York. 1977.
15b. S. Gad and C.S. Weil. ‘‘Statistics
and Experimental Design for the
Toxicologist.’’ Telford Press, NJ. 1986.
15c. M. Hollander and D.A. Wolfe.
‘‘Non parametric Statistical Methods.’’
John Wiely & Sons. New York. 1973.
15d. R.R. Holson et al., 2007.
‘‘Statistical Issues and Techniques
Appropriate for Developmental
Neurotoxicity Testing.’’ Neurotoxicology
and Teratology.
15e. Haseman, Joseph K. 1981.
‘‘Statistical Issues in the Design,
Analysis and Interpretation of Animal
Carcinogenicity Studies.’’ In:
Environmental Health Perspectives, Vol.
58, pp. 385–392.
16a. U.S. Environmental Protection
Agency. ‘‘Guidelines for Reproductive
E:\FR\FM\30JAR1.SGM
30JAR1
5450
Federal Register / Vol. 73, No. 20 / Wednesday, January 30, 2008 / Rules and Regulations
Toxicity Risk Assessment.’’ Federal
Register 61: 56274–56322.
16b. U.S. Environmental Protection
Agency. ‘‘Guidelines for Developmental
Toxicity Risk Assessment.’’ Federal
Register. 56: 63798–63826.
16c. ‘‘An Evaluation and
Interpretation of Reproductive
Endpoints For Human Health Risk
Assessment.’’ International Life Science
Institute. Health and Environmental
Sciences Institute. Developmental and
Reproductive Toxicity Committee.
November 1998.
17. Health Effects Division, Office of
Pesticide Programs, US EPA, ‘‘Data
Evaluation Record: Reproduction and
Fertility Effects Study – Rat; BAS 910 F’’
(March 23, 2002) (EPA Reviewer: Alan
Levy).
18. Office of Prevention, Pesticides
and Toxic Substances, U. S. EPA,
Memorandum from Alan Levy to Yan
Donovan, ‘‘BAS 510 F - Report of the
Hazard Identification Assessment
Review Committee’’ (March 7, 2003).
19. Health Effects Division, Office of
Pesticide Programs, US EPA, ‘‘Data
Evaluation Record: Prenatal
Developmental Toxicity Study – Rabbit;
BAS 910 F’’ (March 23, 2002) (EPA
Reviewer: Alan Levy).
List of Subjects in 40 CFR Part 180
Environmental protection,
Administrative practice and procedure,
Agricultural commodities, Pesticides
and pests, Reporting and recordkeeping
requirements.
Dated: January 17, 2008.
Debra Edwards,
Director, Office of Pesticide Programs.
[FR Doc. E8–1523 Filed 1–29–08; 8:45 am]
BILLING CODE 6560–50–S
ENVIRONMENTAL PROTECTION
AGENCY
40 CFR Part 180
[EPA–HQ–OPP–2006–0481; FRL–8341–6]
Fluopicolide; Pesticide Tolerance
Environmental Protection
Agency (EPA).
ACTION: Final rule.
yshivers on PROD1PC62 with RULES
AGENCY:
SUMMARY: This regulation establishes a
tolerance for residues of fluopicolide,
2,6-dichloro-N-[[3-chloro-5(trifluoromethyl)-2pyridinyl]methyl]benzamide, as an
indicator of combined residues of
fluopicolide and its metabolite, 2,6dichlorobenzamide (BAM), in or on
grape at 2.0 parts per million (ppm);
grape, raisin at 6.0 ppm; vegetable,
VerDate Aug<31>2005
11:37 Jan 29, 2008
Jkt 214001
cucurbit, group 9 at 0.50 ppm;
vegetable, fruiting, group 8 at 1.6 ppm;
vegetable, leafy, except brassica, group 4
at 25 ppm; and vegetable, tuberous and
corm, subgroup, except potato, 1D at
0.02 ppm. Valent U.S.A. Corporation
requested this tolerance under the
Federal Food, Drug, and Cosmetic Act
(FFDCA).
DATES: This regulation is effective
January 30, 2008. Objections and
requests for hearings must be received
on or before March 31, 2008, and must
be filed in accordance with the
instructions provided in 40 CFR part
178 (see also Unit I.C. of the
SUPPLEMENTARY INFORMATION).
ADDRESSES: EPA has established a
docket for this action under docket
identification (ID) number EPA–HQ–
OPP–2006–0481. To access the
electronic docket, go to https://
www.regulations.gov, select ‘‘Advanced
Search,’’ then ‘‘Docket Search.’’ Insert
the docket ID number where indicated
and select the ‘‘Submit’’ button. Follow
the instructions on the regulations.gov
website to view the docket index or
access available documents. All
documents in the docket are listed in
the docket index available in
regulations.gov. Although listed in the
index, some information is not publicly
available, e.g., Confidential Business
Information (CBI) or other information
whose disclosure is restricted by statute.
Certain other material, such as
copyrighted material, is not placed on
the Internet and will be publicly
available only in hard copy form.
Publicly available docket materials are
available in the electronic docket at
https://www.regulations.gov, or, if only
available in hard copy, at the OPP
Regulatory Public Docket in Rm. S–
4400, One Potomac Yard (South Bldg.),
2777 S. Crystal Dr., Arlington, VA. The
Docket Facility is open from 8:30 a.m.
to 4 p.m., Monday through Friday,
excluding legal holidays. The Docket
Facility telephone number is (703) 305–
5805.
FOR FURTHER INFORMATION CONTACT:
Janet Whitehurst, Registration Division
(7505P), Office of Pesticide Programs,
Environmental Protection Agency, 1200
Pennsylvania Ave., NW., Washington,
DC 20460–0001; telephone number:
(703) 305–6129; e-mail address:
whitehurst.janet@epa.gov.
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this Action Apply to Me?
You may be potentially affected by
this action if you are an agricultural
producer, food manufacturer, or
PO 00000
Frm 00030
Fmt 4700
Sfmt 4700
pesticide manufacturer. Potentially
affected entities may include, but are
not limited to those engaged in the
following activities:
• Crop production (NAICS code 111),
e.g., agricultural workers; greenhouse,
nursery, and floriculture workers;
farmers.
• Animal production (NAICS code
112), e.g., cattle ranchers and farmers,
dairy cattle farmers, livestock farmers.
• Food manufacturing (NAICS code
311), e.g., agricultural workers; farmers;
greenhouse, nursery, and floriculture
workers; ranchers; pesticide applicators.
• Pesticide manufacturing (NAICS
code 32532), e.g., agricultural workers;
commercial applicators; farmers;
greenhouse, nursery, and floriculture
workers; residential users.
This listing is not intended to be
exhaustive, but rather to provide a guide
for readers regarding entities likely to be
affected by this action. Other types of
entities not listed in this unit could also
be affected. The North American
Industrial Classification System
(NAICS) codes have been provided to
assist you and others in determining
whether this action might apply to
certain entities. If you have any
questions regarding the applicability of
this action to a particular entity, consult
the person listed under FOR FURTHER
INFORMATION CONTACT.
B. How Can I Access Electronic Copies
of this Document?
In addition to accessing an electronic
copy of this Federal Register document
through the electronic docket at https://
www.regulations.gov, you may access
this Federal Register document
electronically through the EPA Internet
under the ‘‘Federal Register’’ listings at
https://www.epa.gov/fedrgstr. You may
also access a frequently updated
electronic version of EPA’s tolerance
regulations at 40 CFR part 180 through
the Government Printing Office’s pilot
e-CFR site at https://www.gpoaccess.gov/
ecfr.
C. Can I File an Objection or Hearing
Request?
Under section 408(g) of FFDCA, any
person may file an objection to any
aspect of this regulation and may also
request a hearing on those objections.
You must file your objection or request
a hearing on this regulation in
accordance with the instructions
provided in 40 CFR part 178. To ensure
proper receipt by EPA, you must
identify docket ID number EPA–HQ–
OPP–2006–0481 in the subject line on
the first page of your submission. All
requests must be in writing, and must be
mailed or delivered to the Hearing Clerk
E:\FR\FM\30JAR1.SGM
30JAR1
Agencies
[Federal Register Volume 73, Number 20 (Wednesday, January 30, 2008)]
[Rules and Regulations]
[Pages 5439-5450]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-1523]
-----------------------------------------------------------------------
ENVIRONMENTAL PROTECTION AGENCY
40 CFR Part 180
[EPA-HQ-OPP-2005-0145; FRL-8347-3]
Boscalid; Denial of Objections
AGENCY: Environmental Protection Agency (EPA).
ACTION: Final order.
-----------------------------------------------------------------------
SUMMARY: In this order, EPA denies objections filed by the Natural
Resources Defense Council (``NRDC'') to a final rule under section 408
of the Federal Food, Drug, and Cosmetic Act (``FFDCA''), (21 U.S.C.
346a), establishing tolerances for the pesticide boscalid on various
leafy greens. NRDC argues that EPA has unlawfully removed the
additional safety factor for the protection of infants and children
required by Food Quality Protection Act of 1996.
FOR FURTHER INFORMATION CONTACT: Tony Kish, Registration Division,
(7505P), Office of Pesticide Programs, Environmental Protection Agency,
1200 Pennsylvania Ave., NW., Washington, DC 20460-0001; telephone
number: 703-308-9443; e-mail address: kish.tony@epa.gov.
SUPPLEMENTARY INFORMATION:
I. General Information
A. Does this Action Apply to Me?
You may be potentially affected by this action if you are an
agricultural producer, food manufacturer, or pesticide manufacturer.
Potentially affected entities may include, but are not limited to:
Crop production (NAICS code 111), e.g., agricultural
workers; greenhouse, nursery, and floriculture workers; farmers.
Animal production (NAICS code 112), e.g., cattle ranchers
and farmers, dairy cattle farmers, livestock farmers.
Food manufacturing (NAICS code 311), e.g., agricultural
workers; farmers; greenhouse, nursery, and floriculture workers;
ranchers; pesticide applicators.
Pesticide manufacturing (NAICS code 32532), e.g.,
agricultural workers; commercial applicators; farmers; greenhouse,
nursery, and floriculture workers; residential users.
This listing is not intended to be exhaustive, but rather provides
a guide for readers regarding entities that are potentially affected by
this action. Other types of entities not listed in this unit could also
be affected. The North American Industrial Classification System
(NAICS) codes have been provided to assist you and others in
determining whether this action might apply to certain entities. If you
have any questions regarding the applicability of this action to a
particular entity, consult the person listed under FOR FURTHER
INFORMATION CONTACT.
B. How Can I Access Electronic Copies of this Document?
In addition to accessing an electronic copy of this Federal
Register document through the electronic docket at https://
www.regulations.gov, you may access this Federal Register document
electronically through the EPA Internet under the ``Federal Register''
listings at https://www.epa.gov/fedrgstr. You may also access a
frequently updated electronic version of 40 CFR part 180 through the
Government Printing Office's pilot e-CFR site at https://
www.gpoaccess.gov/ecfr.
C. How Can I Access Electronic Copies of Materials in the Docket?
EPA has established a docket for this action under docket
identification (ID) number EPA-HQ-OPP-2005-0145. To access the
electronic docket, go to https://www.regulations.gov, select ``Advanced
Search,'' then ``Docket Search.'' Insert the docket ID number where
indicated and select the ``Submit'' button. Follow the instructions on
the regulations.gov web site to view the docket index or access
available documents.
II. Introduction
A. What Action Is the Agency Taking?
In this order, EPA denies objections filed by the Natural Resources
Defense Council (``NRDC'') to a final rule under section 408 of the
Federal Food, Drug, and Cosmetic Act (``FFDCA''), (21 U.S.C. 346a),
establishing tolerances for the pesticide boscalid on various leafy
greens. (Ref. 1). NRDC argues that EPA must retain an additional ten-
fold (10X) safety factor for the protection of infants and children due
to data showing that juvenile animals are more sensitive than adults.
Retention of this additional safety factor, NRDC contends, shows that
the tolerances are unsafe. Additionally, NRDC contends that EPA's
tolerance decision was arbitrary and capricious because (1) EPA failed
to explain adequately its reason for not applying a 10X safety factor
for infants and children and (2) the safe dose for boscalid established
by EPA is ``clearly contrary to the data . . . .'' (Id. at 3-4, 7-8).
B. What Is the Agency's Authority for Taking This Action?
The procedure for filing objections to tolerance actions and EPA's
authority
[[Page 5440]]
for acting on such objections is contained in section 408(g) of the
FFDCA and regulations at 40 CFR part 178. (21 U.S.C. 346a(g)).
III. Statutory and Regulatory Background
A. Statutory Background
1. In general. EPA establishes maximum residue limits, or
``tolerances,'' for pesticide residues in food under section 408 of the
FFDCA. (21 U.S.C. 346a). Without such a tolerance or an exemption from
the requirement of a tolerance, a food containing a pesticide residue
is ``adulterated'' under section 402 of the FFDCA and may not be
legally moved in interstate commerce. (21 U.S.C. 331, 342). Monitoring
and enforcement of pesticide tolerances are carried out by the U.S.
Food and Drug Administration and the U.S. Department of Agriculture.
Section 408 was substantially rewritten by the Food Quality Protection
Act of 1996 (``FQPA''), which added the provisions discussed below
establishing a detailed safety standard for pesticides and additional
protections for infants and children.
EPA also regulates pesticides under the Federal Insecticide,
Fungicide, and Rodenticide Act (``FIFRA''), (7 U.S.C. 136 et seq).
While the FFDCA authorizes the establishment of legal limits for
pesticide residues in food, FIFRA requires the approval of pesticides
prior to their sale and distribution, (7 U.S.C. 136a(a)), and
establishes a registration regime for regulating the use of pesticides.
FIFRA regulates pesticide use in conjunction with its registration
scheme by requiring EPA review and approval of pesticide labels and
specifying that use of a pesticide inconsistent with its label is a
violation of Federal law. (7 U.S.C. 136j(a)(2)(G)). In the FQPA,
Congress integrated action under the two statutes by requiring that the
safety standard under the FFDCA be used as a criterion in FIFRA
registration actions as to pesticide uses which result in dietary risk
from residues in or on food, (7 U.S.C. 136(bb)), and directing that EPA
coordinate, to the extent practicable, revocations of tolerances with
pesticide cancellations under FIFRA. (21 U.S.C. 346a(l)(1)).
2. Safety standard for pesticide tolerances. A pesticide tolerance
may only be promulgated by EPA if the tolerance is ``safe.'' (21 U.S.C.
346a(b)(2)(A)(i)). ``Safe'' is defined by the statute to mean that
``there is a reasonable certainty that no harm will result from
aggregate exposure to the pesticide chemical residue, including all
anticipated dietary exposures and all other exposures for which there
is reliable information.'' (21 U.S.C. 346a(b)(2)(A)(ii)). Section 408
directs EPA, in making a safety determination, to ``consider, among
other relevant factors- . . . . available information concerning the
aggregate exposure levels of consumers (and major identifiable
subgroups of consumers) to the pesticide chemical residue and to other
related substances, including dietary exposure under the tolerance and
all other tolerances in effect for the pesticide chemical residue, and
exposure from other non-occupational sources.'' (21 U.S.C.
346a(b)(2)(D)(vi)).
Section 408(b)(2)(C) requires EPA to give special consideration to
risks posed to infants and children. Specifically, this provision
states that EPA ``shall assess the risk of the pesticide chemical based
on available information concerning the special susceptibility of
infants and children to the pesticide chemical residues, including
neurological differences between infants and children and adults, and
effects of in utero exposure to pesticide chemicals . . . .'' (21
U.S.C. 346a(b)(2)(C)(i)(II) and (III)). This provision further directs
that ``[i]n the case of threshold effects, . . . an additional tenfold
margin of safety for the pesticide chemical residue and other sources
of exposure shall be applied for infants and children to take into
account potential pre- and post-natal toxicity and completeness of the
data with respect to exposure and toxicity to infants and children.''
(21 U.S.C. 346a(b)(2)(C)). EPA is permitted to ``use a different margin
of safety for the pesticide chemical residue only if, on the basis of
reliable data, such margin will be safe for infants and children.''
(Id.). The additional safety margin for infants and children is
referred to throughout this order as the ``children's safety factor.''
3. Procedures for establishing, amending, or revoking tolerances.
Tolerances are established, amended, or revoked by rulemaking under the
unique procedural framework set forth in the FFDCA. Generally, the
rulemaking is initiated by the party seeking to establish, amend, or
revoke a tolerance by means of filing a petition with EPA. (See 21
U.S.C. 346a(d)(1)). EPA publishes in the Federal Register a notice of
the petition filing and requests public comment. (21 U.S.C.
346a(d)(3)). After reviewing the petition, and any comments received on
it, EPA may issue a final rule establishing, amending, or revoking the
tolerance, issue a proposed rule to do the same, or deny the petition.
(21 U.S.C. 346a(d)(4)). Once EPA takes final action on the petition by
either establishing, amending, or revoking the tolerance or denying the
petition, any affected party has 60 days to file objections with EPA
and seek an evidentiary hearing on those objections. (21 U.S.C.
346a(g)(2)). If objections are filed by a party other than the
petitioner, EPA is required to serve a copy of any objections on the
petitioner. (Id.). EPA's final order on the objections is subject to
judicial review. (21 U.S.C. 346a(h)(1)).
4. Other EPA statutory authority over pesticides. EPA also
regulates pesticides under the Federal Insecticide, Fungicide, and
Rodenticide Act (``FIFRA''), (7 U.S.C. 136 et seq). While the FFDCA
authorizes the establishment of legal limits for pesticide residues in
food, FIFRA requires the approval of pesticides prior to their sale and
distribution, (7 U.S.C. 136a(a)), and establishes a registration regime
for regulating the use of pesticides. FIFRA regulates pesticide use in
conjunction with its registration scheme by requiring EPA review and
approval of pesticide labels and specifying that use of a pesticide
inconsistent with its label is a violation of Federal law. (7 U.S.C.
136j(a)(2)(G)).
B. Evaluating the Safety of Tolerances Through the Use of Risk
Assessment Including the Use of Safety Factors
1. In general. The process EPA follows in evaluating FFDCA
petitions to establish tolerances and in determining the safety of the
petitioned-for tolerances includes two steps. First, EPA determines an
appropriate residue level value for the tolerance taking into account
data on levels that can be expected in food. Second, EPA evaluates the
safety of the tolerance relying on toxicity and exposure data and
guided by the statutory definition of ``safe'' and the statutory
requirements concerning risk assessment. Only on completion of the
second step can EPA make a decision on whether a tolerance may be
established. Below, EPA explains in detail, the reasons for this
approach.
2. Choosing a tolerance value. In the first step of the tolerance
evaluation process (choosing a tolerance value), EPA reviews data from
experimental crop field trials in which the pesticide has been used in
a manner, consistent with the draft FIFRA label, that is likely to
produce the highest residue in the crop in question (e.g., maximum
application rate, maximum number of applications, minimum pre-harvest
interval between last pesticide application and harvest). (Refs. 2 and
3). These crop field trials are generally conducted in several fields
at several geographical locations. (Ref. 3 at pages
[[Page 5441]]
5, 7, and Tables 1 and 5). Several samples are then gathered from each
field and analyzed. (Id. at 53). Generally, the results from such field
trials show that the residue levels for a given pesticide use will vary
from as low as non-detectable to measurable values in the parts per
million (ppm) range with the majority of the values falling at the
lower part of the range. EPA uses a statistical procedure to analyze
the field trial results and identify the upper bound of expected
residue values. This upper bound value is used as the tolerance value.
(Ref. 4). (As discussed below, the safety of the tolerance value chosen
is separately evaluated.).
There are three main reasons for closely linking tolerance values
to the maximum value that could be present from maximum label usage of
the pesticide. First, EPA believes it is important to coordinate its
actions under the two statutory frameworks governing pesticides. (See
61 FR 2378, 2379, January 25, 1996). It would be illogical for EPA to
set a pesticide tolerance under the FFDCA without considering what
action is being taken under FIFRA with regard to registration of that
pesticide use. (Cf. 40 CFR 152.112(g) (requiring all necessary
tolerances to be in place before a FIFRA registration may be granted)).
In coordinating its actions, one basic tenet that EPA follows is that a
grower who applies a pesticide consistent with the FIFRA label
directions should not run the risk that his or her crops will be
adulterated under the FFDCA because the residues from that legal
application exceed the tolerance associated with that use. To further
this goal, crop field trials require application of the pesticide in
the manner most likely to produce maximum residues. Second, choosing
tolerance values based on FIFRA label rates helps to ensure that
tolerance levels are established no higher than necessary. If tolerance
values were selected solely in consideration of health risks, in some
circumstances, tolerance values might be set so as to allow much
greater application rates than necessary for effective use of the
pesticide. This could encourage misuse of the pesticide. Finally,
closely linking tolerance values to FIFRA labels helps EPA to police
compliance with label directions by growers because detection of an
overtolerance residue is indicative of use of a pesticide at levels, or
in a manner, not permitted on the label.
3. The safety determination--risk assessment. Once a tolerance
value is chosen, EPA then evaluates the safety of the pesticide
tolerance using the process of risk assessment. To assess risk of a
pesticide, EPA combines information on pesticide toxicity with
information regarding the route, magnitude, and duration of exposure to
the pesticide.
In evaluating a pesticide's potential hazards (e.g., liver effects,
carcinogenicity), EPA examines both short-term (e.g., ``acute'') and
longer-term (e.g., ``chronic'') adverse effects from pesticide
exposure. (Ref. 2 at 8-10). EPA also considers whether the ``effect''
has a threshold - a level below which exposure has no appreciable
chance of causing the adverse effect. For non-threshold effects, EPA
assumes that any exposure to the substance increases the risk that the
adverse effect may occur. At present, EPA only considers one adverse
effect, the chronic effect of cancer, to potentially be a non-threshold
effect. (Ref. 2 at 8-9). Not all carcinogens, however, pose a risk at
any exposure level (i.e., ``a non-threshold effect or risk''). Advances
in the understanding of carcinogenesis have increasingly led EPA to
conclude that some pesticides that cause carcinogenic effects only
cause such effects above a certain threshold of exposure.
Once the hazard for a durational scenario is identified, EPA must
determine the toxicological level of concern and then compare estimated
human exposure to this level of concern. This comparison is done
through either calculating a safe dose in humans (incorporating all
appropriate safety factors) and expressing exposure as a percentage of
this safe dose (the reference dose (``RfD'') approach) or dividing
estimated human exposure into an appropriately protective dose from the
relevant studies (the margin of exposure (``MOE'') approach). How EPA
determines the level of concern and assesses risk under these two
approaches is explained in more detail below. EPA's general approach to
estimating exposure is also briefly discussed.
a. Levels of concern and risk assessment--i. threshold effects. In
assessing the risk from a pesticide's threshold effects, EPA evaluates
an array of toxicological studies on the pesticide. In each of these
studies, EPA attempts to identify the lowest observed adverse effect
level (``LOAEL'') and the next lower dose at which there are no
observed adverse affect levels (``NOAEL''). Generally, EPA will use the
lowest NOAEL from the available studies, taking into account the route
and duration of exposure, as a starting point in estimating the level
of concern for humans for a given exposure scenario (e.g., acute oral
exposure). This selected NOAEL is usually referred to as the Point of
Departure. In estimating and describing the level of concern, however,
the Point of Departure is at times manipulated differently depending on
whether the risk assessment addresses dietary or non-dietary exposures.
(Refs. 2 at 3-8; 5 at 8, 52-53; and 6).
For dietary risks, EPA uses the Point of Departure to calculate a
safe dose or RfD. The RfD is calculated by dividing the Point of
Departure by applicable safety or uncertainty factors. Typically, a
combination of safety or uncertainty factors providing a hundredfold
(100X) margin of safety is used: 10X to account for uncertainties
inherent in the extrapolation from laboratory animal data to humans and
10X for variations in sensitivity among members of the human population
as well as other unknowns. Further, to account for deficiencies in the
database or the results seen in the database, EPA has traditionally
added additional safety factors on a case-by-case basis. The FQPA
amendments to FFDCA section 408 require an additional safety factor of
10X to protect infants and children (to address data completeness and
pre- and post-natal toxicity concerns), unless reliable data support
selection of a different factor. To some extent, the FQPA safety factor
addresses concerns related to the factors driving EPA's traditional use
of additional safety factors.
In implementing FFDCA section 408, EPA's Office of Pesticide
Programs, also calculates a variant of the RfD referred to as a
Population Adjusted Dose (``PAD''). A PAD is the RfD divided by any
portion of the FQPA children's safety factor that does not correspond
to one of the traditional additional safety factors used in general
Agency risk assessment. (Ref. 5 at 13-16). The reason for calculating
PADs is so that other parts of the Agency, which are not governed by
FFDCA section 408, can, when evaluating the same or similar substances,
easily identify which aspects of a pesticide risk assessment are a
function of the particular statutory commands in FFDCA section 408.
Today, RfDs and PADs are generally calculated for both acute and
chronic dietary risks although traditionally a RfD or PAD was only
calculated for chronic dietary risks. Throughout this document general
references to EPA's calculated safe dose are denoted as a RfD/PAD.
To quantitatively describe risk using the RfD/PAD approach,
estimated exposure is expressed as a percentage of the RfD/PAD. Dietary
exposures lower than 100 percent of the RfD/PAD are generally not of
concern.
[[Page 5442]]
For non-dietary, and often for combined dietary and non-dietary,
risk assessments of threshold effects, the toxicological level of
concern is not expressed as a safe dose or RfD/PAD but rather as the
margin of exposure (MOE) that is necessary to be sure that exposure to
a pesticide is safe. To calculate the MOE for a pesticide for a given
exposure scenario, the expected human exposure to the pesticide is
divided into the dose identified as the Point of Departure. A safe MOE
is generally considered to be a margin at least as high as the product
of all applicable safety factors for a pesticide. For example, if a
pesticide needs a 10X factor to account for interspecies differences, a
10X factor for intraspecies differences, and a 10X FQPA children's
safety factor, the safe or target MOE would be a value of at least
1,000. In contrast to the RfD/PAD approach, the higher the pesticide's
MOE, the safer the pesticide would be considered. Accordingly, if the
target MOE for a pesticide is 1,000, MOE's for that pesticide exceeding
1,000 would generally not be of concern. Like RfD/PADs, specific MOEs
are calculated for exposures of different durations. For non-dietary
exposures, EPA typically examines short-term, intermediate-term, and
long-term exposures. Additionally, non-dietary exposure often involves
exposures by various routes including dermal, inhalation, and oral.
The RfD/PAD and MOE approaches are fundamentally equivalent. For a
given risk and given exposure of a pesticide, if the pesticide were
found to be safe under a RfD/PAD analysis it would also pass under the
MOE approach, and vice-versa.
ii. Non-threshold effects. For risk assessments for non-threshold
effects, EPA does not use the RfD/PAD or MOE approach if quantitation
of the risk is deemed appropriate. Rather, EPA calculates the slope of
the dose-response curve for the non-threshold effects from relevant
studies using a model that assumes that any amount of exposure will
lead to some degree of risk. The slope of the dose-response curve can
then be used to estimate the probability of occurrence of additional
adverse effects as a result of exposure to the pesticide. For non-
threshold cancer risks, EPA generally is concerned if the probability
of increased cancer cases exceed the range of 1 in 1 million.
b. Estimating human exposure. Equally important to the risk
assessment process as identifying hazards and determining the
toxicological level of concern is estimating human exposure. Under
FFDCA section 408, EPA is concerned not only with exposure to pesticide
residues in food but also exposure resulting from pesticide
contamination of drinking water supplies and from use of pesticides in
the home or other non-occupational settings. (See 21 U.S.C.
346a(b)(2)(D)(vi)). There are two critical variables in estimating
exposure in food:
i. the types and amount of food that is consumed; and
ii. the residue levels in that food.
Consumption is estimated by EPA based on scientific surveys of
individuals' food consumption in the United States conducted by the
U.S. Department of Agriculture. (Ref. 2 at 12). Information on residue
levels comes from a range of sources including crop field trials; data
on pesticide reduction due to processing, cooking, and other practices;
information on the extent of usage of the pesticide; and monitoring of
the food supply. (Id. at 17).
In assessing exposure from pesticide residues in food, EPA, for
efficiency's sake, follows a tiered approach in which it, in the first
instance, conducts its initial, screening-level exposure assessment
using the worst case assumptions that 100 percent of the crop in
question is treated with the pesticide and 100 percent of the food from
that crop contains pesticide residues at the tolerance level. (Id. at
11). When such an assessment shows no risks of concern, EPA's resources
are conserved because a more complex risk assessment is unnecessary and
regulated parties are spared the cost of any additional studies that
may be needed. If, however, a first tier assessment suggests there
could be a risk of concern, EPA then attempts to refine its exposure
assumptions to yield a more realistic picture of residue values through
use of data on the percent of the crop actually treated with the
pesticide and data on the level of residues that may be present on the
treated crop. These latter data are used to estimate what has been
traditionally referred to by EPA as ``anticipated residues.'' Use of
percent crop treated data and anticipated residue information is
appropriate because EPA's worst case assumptions of 100 percent
treatment and residues at tolerance value significantly overstate
residue values. (72 FR 52112, July 18, 2007; 71 FR 43906, 43909-43910,
August 2, 2006).
In estimating pesticide exposure levels in drinking water, EPA most
frequently uses mathematical water exposure models rather than
pesticide-specific monitoring data. (69 FR 30042, 30058, May 26, 2004).
EPA's models are based on extensive monitoring data and detailed
information on soil properties, crop characteristics, and weather
patterns. These models calculate estimated environmental concentrations
of pesticides using laboratory data that describe how quickly the
pesticide breaks down to other chemicals and how it moves in the
environment (i.e., does it bind to the soil or is it highly water
soluble). Although computer modeling provides an indirect estimate of
pesticide concentrations, these concentrations can be estimated
continuously over long periods of time, and for places that are of most
interest for any particular pesticide. Modeling is a useful tool for
characterizing vulnerable sites, and can be used to estimate peak
concentrations from infrequent, large storms. Whether EPA assesses
pesticide exposure in drinking water through monitoring data or
modeling, EPA uses the higher of the two values from surface and ground
water in assessing overall exposure to the pesticide. In most cases,
pesticide residues in surface water are significantly higher than in
ground water.
Generally, in assessing residential exposure to pesticides, EPA
relies on its Residential Standard Operating Procedures (``SOPs'').
(Ref. 7). The SOPs establish models for estimating application and
post-application exposures in a residential setting where pesticide-
specific monitoring data is not available. SOPs have been developed for
many common exposure scenarios including pesticide treatment of lawns,
garden plants, trees, swimming pools, pets, and indoor surfaces
including crack and crevice treatments. The SOPs are based on existing
monitoring and survey data including information on activity patterns,
particularly for children. Where available, EPA relies on pesticide-
specific data in estimating residential exposures.
C. Children's Safety Factor Policy
As part of implementation of the major changes to FFDCA section 408
included in the FQPA, EPA has issued a number of policy guidance
documents addressing critical science issues. On January 31, 2002, EPA
released its science policy guidance on the children's safety factor.
(Ref. 5) [This policy is hereinafter referred to as the ``Children's
Safety Factor Policy'']. The Children's Safety Factor Policy emphasizes
throughout that EPA interprets the children's safety factor provision
as establishing a presumption in favor of application of an additional
10X safety factor for the protection of infants and children. (Id. at
4, 11, 47, A-6). Further, the policy notes that the children's safety
factor provision permits a different safety factor to be
[[Page 5443]]
substituted for this default 10X factor only if reliable data are
available to show that the different factor will protect the safety of
infants and children. (Id.). Given the wealth of data available on
pesticides, however, the policy indicates a preference for making an
individualized determination of a protective safety factor if possible.
(Id. at 11). The policy states that use of the default factor could
under- or over-protect infants and children due to the wide variety of
issues addressed by the children's safety factor. (Id.). Further, the
policy notes that ``[i]ndividual assessments may result in the use of
additional factors greater or less than, or equal to 10X, or no
additional factor at all.'' (Id.).
In making pesticide-specific assessments regarding the magnitude of
the children's safety factor, the policy stresses the importance of
focusing on the statutory language that ties the children's safety
factor to concerns regarding potential pre- and post-natal toxicity and
the completeness of the toxicity and exposure databases. (Id. at 11-
12). As to the completeness of the toxicity database, the policy
recommends use of a weight-of-the-evidence approach which considers not
only the presence or absence of data generally required under EPA
regulations and guidelines but also the availability of ``any other
data needed to evaluate potential risks to children.'' (Id. at 20). The
policy indicates that the principal inquiry concerning missing data
should center on whether the missing data would significantly affect
calculation of a safe exposure level. (Id. at 22; accord 67 FR 60950,
60955, September 27, 2002) (finding no additional safety factor
necessary for triticonazole despite lack of developmental neurotoxicity
(``DNT'') study because the ``DNT [study] is unlikely to affect the
manner in which triticonazole is regulated.'')). When the missing data
are data above and beyond general regulatory requirements, the policy
states that the weight of evidence would generally only support the
need for an additional safety factor where the data ``is being required
for `cause,' that is, if a significant concern is raised based upon a
review of existing information, not simply because a data requirement
has been levied to expand OPP's general knowledge.'' (Ref. 5 at 23).
As to potential pre- and post-natal toxicity, the Children's Safety
Factor Policy lists a variety of factors that should be considered in
evaluating the degree of concern regarding any identified pre- or post-
natal toxicity. (Id. at 27-31). As with the completeness of the
toxicity database, the policy emphasizes that the analysis should focus
on whether any identified pre- or post-natal toxicity raises
uncertainty as to whether the RfD/PAD is protective of infants and
children. (Id. at 31). Once again, the presence of pre- or post-natal
toxicity, by itself, is not regarded as determinative as to the
children's safety factor. Rather, the policy stresses the importance of
evaluating all of the data under a weight-of-evidence approach focusing
on the safety of infants and children. (Id.).
In evaluating the completeness of the exposure database, the policy
explains that a weight-of-the-evidence approach should be used to
determine the confidence level EPA has as to whether the exposure
assessment ``is either highly accurate or based upon sufficiently
conservative input that it does not underestimate those exposures that
are critical for assessing the risks to infants and children.'' (Id. at
32). EPA describes why its methods for calculating exposure through
various routes and aggregating exposure over those routes generally
produce conservative exposure estimates - i.e. health-protective
estimates due to overestimation of exposure. (Id. at 40-43).
Nonetheless, EPA emphasizes the importance of verifying that the
tendency for its methods to overestimate exposure in fact were
adequately protective in each individual assessment. (Id. at 44).
IV. The Challenged Tolerances
Boscalid is a fungicide used both on agricultural food crops as
well as turf. It has a wide variety of agricultural uses including
berries, nuts, soybeans, and various vegetables. (40 CFR 180.589(a)).
Tolerances have also been established to cover inadvertent residues on
various other crops as a result of rotation of these crops onto fields
previously treated with boscalid. (40 CFR 180.589(d)). On December 20,
2006, EPA promulgated new boscalid tolerances for residues in or on
leafy greens crop subgroup 4A, except head and leaf lettuce, and leafy
petioles crop subgroup 4B. (71 FR 76185, December 20, 2006).
In promulgating these tolerances, EPA assessed the risk from
boscalid based on aggregate boscalid exposure. Animal studies indicated
that repeat dosing with boscalid resulted in effects in the liver and/
or thyroid in various species. Mechanistic studies indicated that the
thyroid effects were derivative of enzymatic effects on the liver.
(Ref. 8 at 4). The chronic RfD/PAD was based on the results of three
studies that showed similar effects at similar levels. (Id. at 23-24).
The boscalid database showed no effects that were attributable to a
single dose, and thus boscalid was deemed not to pose an acute risk.
Testing involving in utero and/or post-natal exposure of animals showed
no developmental or reproductive effects; however, this testing
resulted in some findings of qualitative or quantitative sensitivity
with regard to body weight effects in the young. EPA concluded there
was low concern regarding these sensitivity findings for various
reasons including that clear NOAELs were identified for these effects
and the effects were transient in nature or inconsistent. EPA assessed
exposure to boscalid in food relying on the worst case assumption that
boscalid residues in all crops to which boscalid may be legally applied
had residues at the tolerance level.
EPA concluded that chronic exposures to boscalid did not raise
safety concerns because the most highly exposed population subgroup,
children 1-2 years old, had exposures below the PAD or safe dose
(exposure was at 38 percent of the PAD). (71 FR 76188). Short-term
exposures from golf course turf was also judged to be safe having a MOE
of 1,400. (Id.). EPA concluded the cancer risk posed by boscalid was
negligible given the weak evidence of carcinogenicity in animal
studies. (Id. at 76189). In conducting these assessments, EPA
determined that the children's safety factor could be removed because
the database was complete, there was low concern for increased
sensitivity in the young, and exposure had been estimated in a
conservative fashion. (Id. at 76188).
V. NRDC's Objections
On February 20, 2007, NRDC filed objections to the December 2006
rule establishing tolerances for boscalid on various leafy greens.
(Ref. 1). On May 21, 2007, NRDC supplemented and expanded its
objections by filing comments during the comment period held by EPA on
NRDC's initial objections. (Ref. 9).
NRDC's objections have two main thrusts: (1) that EPA erred in
removing the children's safety factor given the finding of that young
animals had increased sensitivity to boscalid; and (2) that EPA's
decision is arbitrary and capricious due to a failure to adequately
explain its reasons for removing the children's safety factor and
because EPA's selection of NOAELs and the RfD/PAD ``are clearly
contrary to the data.'' (Ref. 1).
With regard to increased sensitivity in young animals, NRDC relied
in its objections principally on the EPA
[[Page 5444]]
finding in the DNT study that rat pups had decreased body weight and
decreased body weight gain at a dose of 147 milligrams/kilogram of body
weight/day (mg/kg/day) whereas no effects were seen in the maternal
animals even at the highest dose tested (1,442 mg/kg/day). Further,
NRDC cites the rat reproduction study as evidencing increased
sensitivity in rat pups. Given this sensitivity, NRDC argues that it
was wrong for EPA to rely on a study on adult animals to set the RfD/
PAD without retaining the children's safety factor. In addition to
arguing that EPA did not give proper weight to its findings of
increased sensitivity to the young, NRDC claims that EPA analyzed the
data in several studies in a manner that understates the sensitivity of
the young and has selected a RfD/PAD that is under-protective of the
young. (NRDC's arguments on these points are presented in more detail
in Unit VII.A. below.). EPA's allegedly improper analysis is cited as
grounds for retaining the children's safety factor. NRDC claims that if
EPA had retained the children's safety factor it could not have
concluded that the boscalid tolerances are safe.
NRDC makes no new arguments to justify its claim that EPA's
decision is arbitrary and capricious; rather, NRDC merely cross-
references its earlier assertions regarding EPA's interpretation of
science data.
In its comments on its objections, NRDC expands on these arguments.
First, it argues that EPA erred in discounting the seriousness of the
increased sensitivity in the DNT and rat reproduction studies. NRDC
claims that EPA's analysis is based on nothing more than speculation.
(Ref. 9 at 2-4). Second, NRDC cites a third study as showing
sensitivity in young animals, the rabbit developmental study, and
argues similarly that EPA has relied on nothing more than speculation
to conclude that the demonstrated sensitivity is of low concern.
Finally, NRDC provides greater detail in support of its argument that
EPA's selection of a RfD/PAD for boscalid is not protective of children
and does not justify removal of the children's safety factor.
VI. Public Comments
Upon receipt of the objections, EPA provided a copy of the
objections to the tolerance petitioner, BASF Corporation, as required
by the statute. Further, on March 28, 2007, EPA published a notice of
the availability of the objections and established a 60-day comment
period. (72 FR 14551, March 28, 2007). Other than from BASF, EPA
received significant comments only from NRDC - commenting on its own
objections.
BASF's comments stressed that a complete database had been
submitted on boscalid including neurotoxicity studies that went beyond
the core toxicology database requirements. In addition, BASF asserted
that these studies showed ``no toxicologically meaningful effects [in
young animals] were observed at a dose below one that produced toxicity
to the parental animals.'' (Ref. 10 at 2). BASF contended that effects
in rat pups in the DNT and the two-generation reproduction study that
occurred at doses lower than effects in maternal animals were small
and/or transient decreases in pup body weight. (Id.).
Because NRDC's comments on its own objections were a
supplementation of its objections, these comments were provided to BASF
and BASF was given a 30-day period for response. (Ref. 11). As to
NRDC's new arguments concerning sensitivity in the young, BASF asserts
that the data did not support that conclusion. As regards the two-
generation reproduction study and the DNT, BASF notes that, although
toxicity in the parental animals was not seen in the DNT study and was
seen only at the high dose in the reproduction study, in the chronic/
carcinogenicity study in rat, where systematic toxicity is examined
more thoroughly, adverse effects were seen at doses corresponding to
the mid and high doses in the DNT and reproduction studies. Thus, BASF
concludes that the findings of adverse effects in the young at the mid
and high doses in the DNT and reproduction studies do not show
increased sensitivity in the young. As to the rabbit developmental
study, BASF argues that, because the effects on the fetuses (increased
number of abortions) occurred at a dose that showed the maternal
animals were under stress (decreased weight gain), the study does not
show increased sensitivity in the fetuses. According to BASF, ``[t]he
rabbit is prone to spontaneously abort as a response to maternal
stress, and feed restriction alone during the gestational period may
trigger abortions in rabbits.'' (Id. at 3). Finally, BASF defends EPA's
use of the NOAEL from the chronic dog study as the Point of Departure
for setting the cRfD/PAD by presenting a ``benchmark dose'' analysis of
the relevant studies. Benchmark dose analysis involves fitting a
mathematical model to the dose response data for the purpose of
estimating the threshold effect level (i.e., the no adverse effect
level) reflecting a selected benchmark response (e.g., 5%, 10%). BASF's
benchmark dose analysis revealed that the NOAEL from the chronic dog
study was lower than the benchmark dose from DNT and two-generation
reproduction studies.
VII. EPA's Response to the Objections
For the reasons stated below, EPA denies each of NRDC's objections.
A. NRDC's Challenge to EPA's Children's Safety Factor Determination
NRDC contends that EPA's decision to remove the children's safety
factor was erroneous based on (1) the legal argument that whenever EPA
identifies increased sensitivity in the young it is required to retain
the full 10X children's safety factor; and (2) the scientific claim
that EPA did not have a reasoned basis for its conclusion that the
sensitivity identified in animal studies was of low concern in
evaluating whether the 10X children's safety factor should be retained
or a different factor selected.
Before reaching the merits of these arguments, one preliminary
matter needs to be addressed. In a prior order on an objection to EPA's
removal of the children's safety factor as to different pesticides, EPA
denied the objection where retention of the children's safety factor
would not have altered EPA's conclusion on the pesticide's safety (72
FR 39318, 39323-39324, July 18, 2007). For boscalid, the retention/
removal decision appears to be critical to the safety determination
because EPA concluded that chronic exposure to boscalid for the highest
exposed population subgroup is at 38 percent of the RfD/PAD. If no
other change is made to the boscalid risk assessment other than
retaining the 10X children's safety factor, then the calculation that
boscalid exposure uses 38 percent of the RfD/PAD for the most highly-
exposed subgroup would increase by a factor of 10. Because of the
conservativeness of the exposure assessment for boscalid (assuming all
foods that may be legally treated bear tolerance level residues),
however, EPA strongly suspects that a more realistic exposure
assessment will not show a risk of concern. Exposure refinements from
the worst case assumptions of all foods containing tolerance level
residues generally reduce exposure estimates by an order of magnitude
or more. (70 FR 46706, 46732, August 10, 2005). Nonetheless, because
EPA has not completed a revised risk assessment for boscalid at this
time, it will address in this order the substance of NRDC's challenge
to EPA's decision on the children's safety factor. It should be noted
that EPA's decision on the children's safety factor for boscalid relied
in part on the conservativeness of EPA's exposure
[[Page 5445]]
assessment. This consideration continues to be relevant, even if, at
this point, it does obviate NRDC's objection entirely.
1. NRDC's legal argument. NRDC argues that, because section 408
``requires that the additional FQPA tenfold safety factor `shall be
applied' to `take into account' `potential pre- and post-natal
toxicity,'' . . . [t]he clear evidence that juveniles are significantly
more vulnerable than adults compels EPA to retain or increase the
default FQPA tenfold safety factor for boscalid.'' (Ref. 1 at 3).
On repeated occasions EPA has rejected the interpretation that the
children's safety factor provision mandates that the absence of a
particular study or a finding of pre- or post-natal toxicity or
increased sensitivity in the young removes EPA's discretion to choose a
different safety factor. (72 FR 52108, 52115-52117, September 12, 2007;
71 FR 43906, 43919, August 2, 2006). EPA explained its rationale
recently in responding to NRDC objections which made precisely the same
argument in this case:
The statute does direct EPA to consider ``susceptibility of
infants and children'' to pesticides. (21 U.S.C.
346a(b)(2)(C)(i)(II)). It also states that an additional safety
factor to protect infants and children shall be applied ``to take
into account potential pre- and post-natal toxicity . . . .'' (21
U.S.C. 346a(b)(2)(C)). Nonetheless, in clear and unmistakable
language, Congress decreed that, ``[n]otwithstanding such
requirement for an additional margin of safety'' to take into
account potential pre- and post-natal toxicity, EPA is authorized to
choose a different safety factor if EPA has reliable data showing a
different factor is safe. (Id.). Interpreting the statute as
creating a rigid, per se rule that the identification of sensitivity
in the young removes EPA's discretion to choose a different safety
factor is inconsistent with this language and the flexibility
granted to the Agency.
(72 FR at 52117). NRDC has raised no arguments in its current
objections which convince EPA to vary from its long-held
interpretation.
2. NRDC's scientific argument. NRDC makes five claims as to why the
evidence on increased sensitivity in the young is of such significance
that it was inappropriate for EPA to remove the children's safety
factor. NRDC also argues that an alleged lack of reliable data
supporting EPA's derivation of the boscalid RfD/PAD demonstrates that
it was unlawful to remove the children's safety factor. Each claim is
addressed in turn below.
a. The degree of increased sensitivity seen in the DNT. NRDC claims
that adverse effects on auditory startle reflex were seen at all doses
in the offspring in the DNT study and thus the dose EPA identified as a
NOAEL for the offspring (14 mg/kg/day) is actually a LOAEL. According
to NRDC, this demonstrates a higher degree of sensitivity in the
offspring. NRDC notes that a draft EPA assessment of the DNT study
concluded that there were adverse effects on the auditory startle
reflex in offspring at all tested doses. The final EPA review of the
DNT study took the opposite position: that there was not a significant
effect on the auditory startle reflex at any dose. NRDC argues that
EPA's final review is flawed because EPA misused data on the historical
level of the auditory startle reflex in rat controls in other studies
(``historical control data''). According to NRDC, EPA erred by
comparing historical control data to the results in the treated animals
in the boscalid DNT study to determine if the treated animals varied
from control animals generally. NRDC argues that the only valid use of
historical control data is as a check on whether there is a problem
with the controls in a particular study.
EPA disagrees with NRDC's analysis and reaffirms its conclusion
that boscalid did not elicit an adverse effect on auditory startle
reflex in the DNT study. In its initial analysis of the DNT, an EPA
reviewer concluded that there were treatment-related decreases in
auditory startle reflex at all doses on post-natal-day (``PND'') 24.
This finding was based on a statistically significant decrease in
auditory startle reflex in males at both the low and high doses in the
first block of five trials and for the average effect over all trials.
The average decrease was greater in the low dose group (24%) than the
high dose group (19%). The mid-dose group had a slightly lower decrease
of 15%. In females, a statistically significant effect was only seen in
the second block of the low and mid-dose groups but no such effect was
seen for the average across blocks. Again, there was no dose-response
effect in that greater decreases were seen at the low dose than at the
mid or high dose. No statistically significant effects on auditory
startle reflex were seen on PND 60. Noting the ``limitations'' in the
data, the EPA reviewer nonetheless tentatively found a treatment-
related effect at all doses.
In response to this tentative conclusion, the boscalid registrant
submitted historical control data on auditory startle reflex and data
concerning one male pup that died on PND 25. After examining the
historical control data, EPA concluded that the auditory startle reflex
of the controls from the boscalid DNT study were similar to historical
controls and thus the controls from the boscalid study ``should be
considered the primary source for analysis and consideration'' for this
study. (Ref. DER at 30). As to the rat which died, EPA concluded that
it was suffering from an underlying illness unrelated to treatment and
removed its data from the study. As a result, none of the individual
block trials nor the average from all trials for males evidenced a
statistically significant decrease in auditory startle reflex at PND
24. EPA also reanalyzed the statistical significance of the results for
the females and found a statistically significant effect only at the
low dose for the second block. Given the revised finding of a
statistically significant effect in only one block trial (out of five)
at one dose (out of three) in one sex on one day of testing (out of
two) and the lack of a dose response (effects only at the low dose),
EPA concluded that there was no treatment-related effect on auditory
startle reflex.
NRDC's objection here is denied. As a preliminary matter, EPA would
note that it disagrees with NRDC's claim that historical control data
can only be used for the narrow purpose of evaluating the fitness of a
study's controls. (Refs. 12a, 12b, and 12c). This disagreement,
however, is beside the point because for the boscalid DNT study EPA
used historical control data in precisely the manner that NRDC argues
they should be used. EPA's review of the DNT specifically found that
``[h]istorical control data provided indicated that the mean startle
amplitude on PND 24 for the current study of [boscalid] was similar to
the control means of the submitted studies on PND 24. Therefore the
analysis of this group's relation to treatment groups is valid and
should be considered the primary source for analysis and evaluation.''
(Ref. 13 at 30). Finally, EPA's conclusion that the DNT study showed no
treatment-related effect on auditory startle reflex was based upon a
reasonable evaluation of the data, as demonstrated above.
b. The sensitivity of DNT Study. NRDC claims that the DNT study is
an insensitive study because it involves examination of only one male
and one female pup per litter and that therefore EPA should have
attached more significance to the finding of increased sensitivity in
the young in that study. NRDC also criticizes the statistical analysis
of the DNT study for only including probability values (``p-values'')
representing confidence levels of 95 percent (p-value of 0.05) and 99
percent (p-value of 0.01). (Basically, a p-value defines the
probability that an observed difference between a control group and a
treatment group is based on
[[Page 5446]]
chance alone.). NRDC argues that rather than analyze the data against
the p-values of 0.05 and 0.01, EPA should calculate the ``actual p-
value statistic,'' and thus EPA could use its ``expert judgment on the
significance of the findings, given the limitations of the study.''
(Ref. 1 at 5).
EPA believes that the significance attached to findings of
sensitivity in a DNT study should be driven primarily by an evaluation
of the results of the study itself. EPA would note that the development
and design of the DNT study underwent an exhaustive independent
scientific peer review as well as public comment process. (Ref. 14).
This process included multiple reviews by EPA's FIFRA Scientific
Advisory Panel and public comment opportunities as well as a scientific
workshop involving outside experts organized expressly to evaluate
developmental neurotoxicity testing issues. (Id.). NRDC's criticisms of
use of reporting statistical significance at the 95 and 99 percent
confidence levels are misplaced. Use of p-values of 0.01 and 0.05 to
document statistically significant differences between treated and
control animal groups is a long-established practice in the scientific
community. (Refs. 15a, 15b, 15c, 15d, and 15e). EPA can calculate
different levels of statistical confidence if for some reason the data
suggest that may be valuable; however, in EPA's judgment no such
reasons were present in the circumstances of the boscalid DNT study.
c. Weight-of-the-evidence evaluation of the two-generation
reproduction study in rats. NRDC argues that EPA undervalues the
importance of increased sensitivity identified in the two generation
reproduction study in rats based on nothing more than speculation.
According to NRDC, EPA was just ``guess[ing]'' when it stated that:
``The degree of concern is also low for the quantitative evidence of
susceptibility seen in the 2-generation reproduction study in rats
because the decreases in body weight and body weight gains were seen
primarily in the [second] generation. These may have been due to
exposure of the parental animals to high doses (above the Limit
Dose).'' (Ref. 9 at 2 (citing to 76 FR 76188) (emphasis added by
NRDC)). NRDC also suggests that EPA's ``speculation'' is
``nonsensical'' because if the second generation pups had effects due
to high dose exposures of the parents, then these effects should have
been seen in the first generation pups because their parents had the
same high dose exposures.
In comments on NRDC's objections, BASF argues that young animals
are not more sensitive to boscalid than adult animals given that adult
animals in the chronic/carcinogenicity study in the rat experienced
adverse effects at similar dose levels as the pups in the two
generation rat study. BASF makes the same contention with regard to the
DNT study. (See Unit VII.A.2.d., below).
EPA does not believe that the sensitivity evidenced in the pups in
the two-generation reproduction requires retention of the 10X
children's safety factor. As discussed in detail in Unit VII.A.2.f.,
the NOAEL from the chronic dog study used for the Point of Departure in
setting the chronic RfD/PAD for the liver effects is protective of the
body weight effects seen in the second generation male pups at mid and
high doses in the two-generation reproduction study. EPA disagrees with
NRDC that it was somehow improper to take into account that the body
weight effects in the pups in the two-generation reproduction study
were only seen in males and only in the second generation. These
factors bear on significance of the effects seen. Effects seen in only
one sex and only after dosing for two generations are generally
regarded as less significant than effects seen in both sexes and in
both generations of a two-generation study. Moreover, there is other
evidence from the study suggesting that body weight effects in the
young were not entitled to great weight in EPA's weight-of-the-evidence
analysis. First, absolute body weight and bodyweight gain of the male
F2 offspring of treated dams were similar to those of the
offspring of the control dams at birth. Birth is a more sensitive time
point to indicate susceptibility than subsequent time periods. (Refs.
16a, 16b, and 16c). Second, there was a lack of consistency in the
observed body weight decreases (i.e, decreased on days 7 and 21 but not
on days 4 and 17). (Ref. 17 at 20). EPA believes these factors are
important to informing its expert judgment regarding the level of
concern regarding, or the significance of, the increased sensitivity
observed in this study. In any event, EPA's determination that the
chronic RfD/PAD is protective of the pup effects seen in the
reproduction study is alone sufficient to allay any concerns regarding
increased sensitivity and pre- and post-natal toxicity raised by the
two-generation reproduction study.
NRDC places special emphasis on EPA's suggestion that the body
weight effect may be due to the very high dose given the maternal
animals. EPA's statement on this issue was in error because, as noted,
the body weight effects were seen at both the mid and high doses in the
study in the second generation pups. Nonetheless, for the reasons
described above, identification of a clear NOAEL for body weight
effects and limited nature of the body weight effects (e.g., one sex
only, inconsistent findings at the mid dose), EPA concludes that the
chronic RfD/PAD based on a safety factor of 100X is safe for infants
and children.
EPA does not agree that BASF has made an appropriate comparison of
the results of the two-generation reproduction study and the chronic/
carcinogenicity study given the substantial difference in time of
exposure to boscalid in the two studies.
d. Weight-of-the-evidence evaluation of the DNT Study. NRDC argues
that EPA errs in downplaying the significance of the decreased weight
gain in pups seen in the DNT. NRDC states that EPA found there to be
low concern for the decreases in pup body weight on post-natal days 1-4
because no effects on body weight were seen at any other time and the
effects only occurred when the maternal animals were receiving an
extremely high dose (above the Limit Dose) suggesting that pup effects
were derivative of effects on the maternal animals. This reasoning is
attacked by NRDC as mere speculation. NRDC claims that ``the Agency
does not and cannot assert that inadequate weight gain on days 1-4 is
an insignificant adverse effect. Any significant reduction in weight
gain during early development is potentially harmful and may cause
permanent adverse effects.'' (Ref. 9 at 3). Further, NRDC states that
EPA has presented no empirical evidence to support its conclusion that
the high dose to the maternal animals might have been the reason for
the pup effect.
For similar reasons to those relied upon in rejecting NRDC's
arguments concerning the two-generation reproduction study, EPA does
not believe that the sensitivity evidenced in the pups in the DNT study
requires retention of the 10X children's safety factor. As discussed in
detail in Unit VII.A.2.f., the NOAEL from the chronic dog study used
for the Point of Departure in setting the chronic RfD/PAD for the
liver/thyroid effects is protective of the transient body weight
effects seen in the pups at mid dose and the more severe pup body
weight effects at the high dose in the DNT study. EPA disagrees with
NRDC that it was somehow improper to take into account that the body
weight effects in the mid-dose pups were transient in nature - i.e.,
statistically significant decreases in body weight were seen on post-
natal
[[Page 5447]]
days 1-4 but the animals had recovered by day 11. The severity of an
effect aids in evaluation of the dose response curve for a pesticide;
in this case, it indicates that mid dose was not far from the actual no
adverse effect level. In any event, EPA's determination that the
chronic RfD/cPAD is protective of the pup effects seen in the DNT study
is alone sufficient to allay any concerns regarding increased
sensitivity and pre- and post-natal toxicity raised by the DNT study.
NRDC challenges EPA's reasoning that the effects on pups' body
weight may be due to the maternal animals being exposed above the Limit
Dose. The Limit Dose is regarded as the highest dose possible that can
be given an animal without overwhelming its defense mechanisms. As a
general matter, EPA does not believe NRDC's argument is well-founded
because discounting the weight of effects seen only at or above the
Limit Dose is a well-accepted scientific precept. Here, however, EPA
erred by mentioning the Limit Dose because effects were present in the
pups at the mid dose as well as at the dose that exceeded the Limit
Dose. Nonetheless, for the reasons described above, identification of a
clear NOAEL for body weight effects and limited nature of the body
weight effects (e.g., one sex only, transient nature of effects at the
mid dose), EPA concludes that the RfD/PAD based on a safety factor of
100X is safe for infants and children.
For the same reason as stated in Unit VII.A.2.c., EPA disagrees
with BASF's comparison of the DNT study and the chronic/carcinogenicity
study.
e. Weight-of-the-evidence evaluation of the rabbit developmental
study. NRDC claims that EPA wrongfully disregards the qualitative
evidence of increased sensitivity seen in the rabbit developmental
study. According to NRDC, EPA expressed a low degree of concern for
increased abortions or early delivery effects on the young because they
were seen only at the Limit Dose and may have been caused by maternal
stress. NRDC faults EPA for not providing empirical evidence to support
this conclusion and argues that the Limit Dose might not be the maximum
tolerated dose for boscalid in rabbits. This type of ``speculation,''
NRDC claims, cannot meet the ``reliable data'' requirement for choosing
a different children's safety factor.
NRDC's claims as to the rabbit developmental study, have even less
merit than its arguments as to the two-generation reproduction and DNT
studies. Not only is the chronic RfD/PAD for the thyroid effects
protective of the qualitative sensitivity seen in the rabbit
developmental study but the chronic RfD/cPAD is protective by an order
of magnitude of an effect seen only at a ``limit dose.'' The chronic
RfD/PAD is based on a NOAEL from the chronic dog study of 21.8 mg/kg/
day as compared to the NOAEL for the fetal effects in the rabbit
developmental study of 300 mg/kg/day. The fetal effects (abortions and
early delivery) were seen only at the Limit Dose. (Unlike in the two-
generation reproduction and DNT studies, adverse effects were only seen
in the young at the high dose.). Moreover, the fetal effects were seen
only in the presence of adverse effects in the maternal animals. The
primary adverse effects in the maternal animals were abortions and
early delivery (considered an adverse effect on both maternal animals
and fetuses) but the study evidenced decreased food consumption and
decreased body weight in the maternal animals as well. Although a
definitive conclusion was not reached on whether the food consumption
effects were treatment-related, evaluation of the individual animals
showed that three of the four does that aborted or delivered early
experienced dramatic reductions in food consumption. Given these
results, it was reasonable for EPA to take into account its scientific
expertise with rabbit toxicology studies which indicated that maternal
animals put under stress had a tendency to abort or deliver early.
Based on all of this evidence, EPA rejects NRDC's arguments concerning
the rabbit developmental study and concludes that the qualitative
sensitivity evidenced in the fetuses in the rabbit developmental study
does not require retention of the 10X children's safety factor. (Refs.
18 and 19).
f. Derivation of the chronic RfD/PAD. NRDC claims that EPA erred in
its selection of a NOAEL to calculate the chronic RfD/PAD by not
relying on the lowest NOAEL from the applicable chronic studies. (Ref.
1 at 5-6). NRDC argues that, because EPA's justification for the RfD/
PAD is allegedly nothing more than speculation, EPA lacks the reliable
data necessary to remove the children's safety factor. (Ref. 9 at 4-5).
EPA relied on three co-critical studies in selecting a NOAEL for
the chronic RfD/PAD: chronic toxicity in the rat, carcinogenicity in
the rat, and chronic toxicity in the dog. Each of these studies showed
liver effects and the rat studies also evidenced secondary effects on
the thyroid. The NOAELs for the studies tightly bunched between 21.8
and 30 mg/kg/day. EPA selected the 21.8 mg/kg/day NOAEL from the
chronic dog study to calculate the chronic RfD/PAD. EPA considered but
rejected lower NOAELs from three other studies: the 90-day subchronic
toxicity study in the dog; the two-generation reproduction study in the
rat; and the developmental neurotoxicity study. EPA's rationale for not
using the NOAELs from these studies was that the lower NOAELs from
these studies were an artifact of dose selection given the wide range
between NOAEL and LOAEL in the studies and the minimal effects seen at
the LOAEL.
NRDC challenges EPA's conclusion claiming that EPA has ignored
``effects at significantly lower doses in juvenile animals (2-gen repro
and DNT).'' (Ref. 1 at 4). NRDC also argues that EPA's decis